Pharmaceutical chemistry and technology Books

Book SynopsisAlthough a wealth of knowledge is available on how best to reduce the burden of stroke and infectious neurological diseases, intervention and reduction of the burden of other non-communicable neurological disorders is much more complex and requires the development of new and more effective treatments and prevention measures. This book addresses this demand by collecting key elements required in developing novel treatments for non-communicable neurological disorders. Key chapters include the blood-brain barrier's important role in the treatment of neurological disorders, physiological barriers for drug delivery to brain, novel drug delivery systems and industrial production and regulatory aspects.Key Features Summarizes key in vitro and in vivo evaluations that should be considered in developing successful brain drug delivery systems. Addresses points that should be considered, when large scales of brain drug delivery systems are produced at the industrial level, and how batch consistencies can be met. Helps formulation scientists to consider important regulatory requirements when developing novel drug delivery systems to brain. Includes an important chapter describing in vivo evaluation of diffusing therapeutic agents from the blood into the brain parenchyma and how this approach would complement the current imaging techniques such IVIS. Provides key information about the use of monoclonal antibodies for the treatment of neurological disorders.

Read more less

Book SynopsisThis revised and updated new edition of a best-selling text remains a fast and convenient overview of the clinical trials in gynecologic cancer treatment, outlining the evidence base of treatment decisions in uterine, ovarian, cervical, and vulvar cancers, and gestational trophoblastic neoplasia. Residents and fellows will find this book an indispensable reference, while practitioners will welcome it as a clarification of the evidence base for treatment options. *Gives a convenient summary of trials in gynecologic oncology *Supplies an invaluable revision primer for those undertaking certification *Provides a uniquely up-to-date resourceTable of ContentsPreface to the second edition1. Uterine Malignancies. 1.1. Endometrial Carcinoma. 1.1.1. Studies addressing surgical treatment. 1.1.1.1. Lymph node assessment 1.1.2. Studies addressing adjuvant therapy. 1.1.2.1. Radiation. 1.1.2.2. Chemoradiation. 1.1.2.3. Chemotherapy. 1.1.3. Studies addressing treatment of recurrent endometrial carcinoma. 1.1.3.1. Hormonal therapy. 1.1.3.2. Chemotherapy. 1.1.3.3. Targeted therapy. 1.1.3.4. Immunotherapy. 1.2. Uterine Carcinosarcoma. 1.2.1. Studies addressing prognosticators. 1.2.2. Studies addressing adjuvant treatment. 1.2.3. Studies addressing treatment of advanced/ recurrent uterine carcinosarcoma. 1.3. Uterine Leiomyosarcoma. 1.3.1. Studies addressing adjuvant treatment of early stage uterine leiomyosarcoma. 1.3.2. Studies addressing treatment of advanced uterine leiomyosarcoma. 1.4. References.2. Ovarian Malignancies. 2.1. Epithelial ovarian cancer (EOC). 2.1.1. Studies addressing upfront surgery. 2.1.2. Studies addressing adjuvant therapy. 2.1.3. Studies addressing intraperitoneal chemotherapy. 2.1.4. Studies addressing first line maintenance treatment. 2.1.5. Studies addressing neoadjuvant therapy. 2.1.6. Studies addressing prediction of debulking. 2.1.7. Studies addressing time point of treatment of recurrence. 2.1.8. Studies addressing treatment of recurrent ovarian cancer, platinum-sensitive. 2.1.8.1. Chemotherapy and targeted therapy. 2.1.8.2. Secondary debulking surgery. 2.1.9. Studies addressing treatment of recurrent ovarian cancer, platinum-resistant. 2.1.9.1. Chemotherapy and targeted therapy. 2.1.9.2. Immunotherapy. 2.2. Low grade serous ovarian cancer. 2.3. Mucinous epithelial ovarian cancer (mEOC). 2.4. Ovarian Germ Cell Tumors (GCT). 2.5. Ovarian Sex Cord-Stromal Tumors (SCT). 2.6. References.3. Cervical Cancer. 3.1. Studies addressing surgical treatment. 3.2. Studies addressing adjuvant therapy. 3.3. Studies addressing primary chemoradiation therapy. 3.4. Studies addressing treatment of recurrent or metastatic cervical cancer. 3.4.1. Chemotherapy and targeted therapy. 3.4.2. Immunotherapy. 3.5. References.4. Vulvar Cancer. 4.1. Studies addressing surgical treatment. 4.1.1. Groin lymph nodes. 4.2. Studies addressing advanced vulvar cancer. 4.2.1. Chemoradiation. 4.2.2. Immunotherapy. 4.3. References.5. Gestational Trophoblastic Neoplasia (GTN). 5.1. Studies addressing surgical treatment. 5.2. Studies addressing chemotherapy in low-risk GTN. 5.3. Studies addressing (chemo)therapy in high-risk GTN. 5.4. References.6. Glossary. Index.

Read more less

Book SynopsisThe book reviews the recent research advances and their outcomes in the areas of structural biology, bioinformatics, phytochemistry and drug discovery. Chapters in the book cover multidisciplinary research to understand the molecular mechanisms involved in protein-protein/ligand interactions. It employs an integrative approach to identify the therapeutic targets for HIV, and cancer, pathogen and viral infection pathways and the identification of their potential drug candidates. The book also provides examples of computational molecular dynamics simulations to understand the conformational changes in the molecules. Some chapters are focused on exploring potent bioactive compounds from natural sources.This book can serve as a single source that covers several interdisciplinary research fields which will be beneficial to Researchers and students in postgraduate studies.

Read more less

Book SynopsisUsing time-to-event analysis methodology requires careful definition of the event, censored observation, provision of adequate follow-up, number of events, and independence or noninformativeness of the censoring mechanisms relative to the event. Design and Analysis of Clinical Trials with Time-to-Event Endpoints provides a thorough presentation of the design, monitoring, analysis, and interpretation of clinical trials in which time-to-event is of critical interest.After reviewing time-to-event endpoint methodology, clinical trial issues, and the design and monitoring of clinical trials, the book focuses on inferential analysis methods, including parametric, semiparametric, categorical, and Bayesian methods; an alternative to the Cox model for small samples; and estimation and testing for change in hazard. It then presents descriptive and graphical methods useful in the analysis of time-to-event endpoints. The next several chapters explore a variety of Trade Review… One of the strengths of the book is the collection, discussion and illustration of the many diverse time-to-event problems that may occur in practice. … this publication provides a comprehensive overview of classical and emerging ideas in the analysis of time-to-event problems. Written by experts in their area, the book has a wealth of references in each topic should the reader wish to learn about or extend their understanding of individual concepts or analysis methods. It is a worthwhile book to have in the library for anyone working in designing, conducting, analysing or interpreting studies with time-to-event outcomes.—Australian & New Zealand Journal of Statistics, 2011Table of ContentsOverview of Time-to-Event Endpoint Methodology. Design (and Monitoring) of Clinical Trials with Time-to-Event Endpoints. Overview of Time-to-Event Parametric Methods. Overview of Semiparametric Inferential Methods for Time-to-Event Endpoints. Overview of Inferential Methods for Categorical Time-to-Event Data. Overview of Bayesian Inferential Methods Including Time-to-Event Endpoints. An Efficient Alternative to the Cox Model for Small Time-to-Event Trials. Estimation and Testing for Change in Hazard for Time-to-Event Endpoints. Overview of Descriptive and Graphical Methods for Time-to-Event Data. Design and Analysis of Analgesic Trials. Design and Analysis of Analgesic Trials with Paired Time-to-Event Endpoints. Time-to-Event Endpoint Methods in Antibiotic Trials. Design and Analysis of Cardiovascular Prevention Trials. Design and Analysis of Antiviral Trials. Cure Rate Models with Applications to Melanoma and Prostate Cancer Data. Parametric Likelihoods for Multiple Nonfatal Competing Risks and Death, with Application to Cancer Data. Design, Summarization, Analysis, and Interpretation of Cancer Prevention Trials. LASSO Method in Variable Selection for Right-Censored Time-to-Event Data with Application to Astrocytoma Brain Tumor and Chronic Myelogenous Leukemia. Selecting Optimal Treatments Based on Predictive Factors. Application of Time-to-Event Methods in the Assessment of Safety in Clinical Trials. Design and Analysis of Chronic Carcinogenicity Studies of Pharmaceuticals in Rodents. Design and Analysis of Time-to-Tumor Response in Animal Studies: A Bayesian Perspective. Index.

Read more less

Book SynopsisClinical trials have become essential research tools for evaluating the benefits and risks of new interventions for the treatment and prevention of diseases, from cardiovascular disease to cancer to AIDS. Based on the authors’ collective experiences in this field, Introduction to Statistical Methods for Clinical Trials presents various statistical topics relevant to the design, monitoring, and analysis of a clinical trial.After reviewing the history, ethics, protocol, and regulatory issues of clinical trials, the book provides guidelines for formulating primary and secondary questions and translating clinical questions into statistical ones. It examines designs used in clinical trials, presents methods for determining sample size, and introduces constrained randomization procedures. The authors also discuss how various types of data must be collected to answer key questions in a trial. In addition, they explore common analysis methods, describe statistical methods that determine what an emerging trend represents, and present issues that arise in the analysis of data. The book concludes with suggestions for reporting trial results that are consistent with universal guidelines recommended by medical journals. Developed from a course taught at the University of Wisconsin for the past 25 years, this textbook provides a solid understanding of the statistical approaches used in the design, conduct, and analysis of clinical trials.Trade Review… There is much good material in this book. The individual chapters are well written and cover the technical aspects as well. A major strength is the ordering of topics to follow the thought process used in the development and implementation of a protocol from defining the question to reporting results. There are careful discussions on fundamental principles and the pivotal role played by statistics is well brought out. … there is much that practicing pharmaceutical statisticians will find useful in this book. They will find the coverage of fundamental principles useful and the technical content of the book a good reference source. …—Pharmaceutical Statistics, 2010… fits the need for a contemporary text and handbook that is oriented toward the clinical trial statistician. I highly recommend it and look forward to using it as both a primary and supplemental text in our curriculum, as well as a research resource.—James J. Dignam, University of Chicago, JASA, March 2009The (technical) statistical content is the main focus of the book and this is what helps it to stand apart from most others on clinical trials (even the more obviously statistically orientated ones). It takes the reader to quite a technical background that would serve him or her well if moving on to research problems in the various areas covered, yet does not lose sight of practical issues. … For those of us with the interest (and need) to grapple with these more statistical issues, I wholeheartedly recommend it.—Biometrics, December 2008…The book is very well written and clear. … the authors generally strike the right balance for the intended audience. The inclusion of many historically important as well as contemporary examples to illustrate various points throughout the text is a major strength, as is the inclusion of several modern topics not seen in other texts. As a basis for a course in clinical trials for graduate students in biostatistics, this book is outstanding. In addition, statisticians in the pharmaceutical industry, government, or academia … will find this text extremely informative and useful.” —Michael P. McDermott, University of Rochester Medical Center, Journal of Biopharmaceutical Statistics, 2008Table of ContentsPreface. Introduction to Clinical Trials. Defining the Question. Study Design. Sample Size. Randomization. Data Collection and Quality Control. Survival Analysis. Longitudinal Data. Quality of Life. Data Monitoring and Interim Analysis. Selected Issues in the Analysis. Closeout and Reporting. Special Topics. Appendix. References. Index.

Read more less

Book SynopsisComputational Drug Discovery A comprehensive resource that explains a wide array of computational technologies and methods driving innovation in drug discovery Computational Drug Discovery: Methods and Applications (2 volume set) covers a wide range of cutting-edge computational technologies and computational chemistry methods that are transforming drug discovery. The book delves into recent advances, particularly focusing on artificial intelligence (AI) and its application for protein structure prediction, AI-enabled virtual screening, and generative modeling for compound design. Additionally, it covers key technological advancements in computing such as quantum and cloud computing that are driving innovations in drug discovery. Furthermore, dedicated chapters that addresses the recent trends in the field of computer aided drug design, including ultra-large-scale virtual screening for hit identification, computational strategies for designing new therapeutic modalities like PROTACs and covalent inhibitors that target residues beyond cysteine are also presented. To offer the most up-to-date information on computational methods utilized in Computational Drug Discovery, it covers chapters highlighting the use of molecular dynamics and other related methods, application of QM and QM/MM methods in computational drug design, and techniques for navigating and visualizing the chemical space, as well as leveraging big data to drive drug discovery efforts. The book is thoughtfully organized into eight thematic sections, each focusing on a specific computational method or technology applied to drug discovery. Authored by renowned experts from academia, pharmaceutical industry, and major drug discovery software providers, it offers an overview of the latest advances in computational drug discovery. Key topics covered in the book include: Application of molecular dynamics simulations and related approaches in drug discovery The application of QM, hybrid approaches such as QM/MM, and fragment molecular orbital framework for understanding protein-ligand interactions Adoption of artificial intelligence in pre-clinical drug discovery, encompassing protein structure prediction, generative modeling for de novo design, and virtual screening. Techniques for navigating and visualizing the chemical space, along with harnessing big data to drive drug discovery efforts. Methods for performing ultra-large-scale virtual screening for hit identification. Computational strategies for designing new therapeutic models, including PROTACs and molecular glues. In silico ADMET approaches for predicting a variety of pharmacokinetic and physicochemical endpoints. The role of computing technologies like quantum computing and cloud computing in accelerating drug discovery This book will provide readers an overview of the latest advancements in Computational Drug Discovery and serve as a valuable resource for professionals engaged in drug discovery.Table of ContentsVolume 1 Preface xv Acknowledgments xix About the Editors xxi Part I Molecular Dynamics and Related Methods in Drug Discovery 1 1 Binding Free Energy Calculations in Drug Discovery 3Anitade Ruiter and Chris Oostenbrink 2 Gaussian Accelerated Molecular Dynamics in Drug Discovery 21Hung N. Do, Jinan Wang, Keya Joshi, Kushal Koirala, and Yinglong Miao 3 MD Simulations for Drug-Target(Un)binding Kinetics 45Steffen Wolf 4 Solvation Thermodynamics and its Applications in Drug Discovery 65Kuzhanthaivelan Saravanan and Ramesh K. Sistla 5 Site-Identification by Ligand Competitive Saturation as a Paradigm of Co-solvent MD Methods 83Asuka A. Orr and Alexander D. MacKerell Jr. Part II Quantum Mechanics Application for Drug Discovery 119 6 QM/MM for Structure-Based Drug Design: Techniques and Applications 121Marc W. van der Kamp and Jaida Begum 7 Recent Advances in Practical Quantum Mechanics and Mixed-QM/MM-Driven X-Ray Crystallography and Cryogenic Electron Microscopy (Cryo-EM) and Their Impact on Structure-Based Drug Discovery 157Oleg Borbulevych and Lance M. Westerhoff 8 Quantum-Chemical Analyses of Interactions for Biochemical Applications 183Dmitri G. Fedorov Part III Artificial Intelligence in Pre-clinical Drug Discovery 211 9 The Role of Computer-Aided Drug Design in Drug Discovery 213Stormvander Voort, Andreas Bender, and Bart A. Westerman 10 AI-Based Protein Structure Predictions and Their Implications in Drug Discovery 227Tahsin F. Kellici, Dimitar Hristozov, and Inaki Morao 11 Deep Learning for the Structure-Based Binding Free Energy Prediction of Small Molecule Ligands 255Venkatesh Mysore, Nilkanth Patel, and Adegoke Ojewole 12 Using Artificial Intelligence for de novo Drug Design and Retrosynthesis 275Rohit Arora, Nicolas Brosse, Clarisse Descamps, Nicolas Devaux, Nicolas Do Huu, Philippe Gendreau, Yann Gaston-Mathé, Maud Parrot, Quentin Perron, and Hamza Tajmouati 13 Reliability and Applicability Assessment for Machine Learning Models 299Fabio Urbina and Sean Ekins Volume 2 Preface xv Acknowledgments xix About the Editors xxi Part IV Chemical Space and Knowledge-Based Drug Discovery 315 14 Enumerable Libraries and Accessible Chemical Space in Drug Discovery 317Tim Knehans, Nicholas A. Boyles, and Pieter H. Bos 15 Navigating Chemical Space 337Akos Tarcsay, András Volford, Jonathan Buttrick, Jan-Constantin Christopherson, Máte Erdos, and Zoltán B. Szabó 16 Visualization, Exploration, and Screening of Chemical Space in Drug Discovery 365José J. Naveja, Fernanda I. Saldívar-González, Diana L. Prado-Romero, Angel J.Ruiz-Moreno, Marco Velasco-Velázquez, Ramón Alain Miranda-Quintana, and José L. Medina-Franco 17 SAR Knowledge Bases for Driving Drug Discovery 395Nishanth Kandepedu, Anil Kumar Manchala, and Norman Azoulay 18 Cambridge Structural Database (CSD)–Drug Discovery Through Data Mining & Knowledge-Based Tools 419Francesca Stanzione, Rupesh Chikhale, and Laura Friggeri Part V Structure-Based Virtual Screening Using Docking 441 19 Structure-Based Ultra-Large Virtual Screenings 443Christoph Gorgulla 20 Community Benchmarking Exercises for Docking and Scoring 471Bharti Devi, Anurag TK Baidya, and Rajnish Kumar PartVI In Silico ADMET Modeling 495 21 Advances in the Application of In Silico ADMET Models–An Industry Perspective 497Wenyi Wang, Fjodor Melnikov, Joe Napoli, and Prashant Desai Part VII Computational Approaches for New Therapeutic Modalities 537 22 Modeling the Structures of Ternary Complexes Mediated by Molecular Glues 539Michael L. Drummond 23 Free Energy Calculations in Covalent Drug Design 561Levente M. Mihalovits, György G. Ferenczy, and György M. Keseru Part VIII Computing Technologies Driving Drug Discovery 579 24 Orion A Cloud-Native Molecular Design Platform 581Jesper Sorensen, Caitlin C. Bannan, Gaetano Calabrò, Varsha Jain, Grigory Ovanesyan, Addison Smith, She Zhang, Christopher I. Bayly, Tom A. Darden, Matthew T. Geballe, David N. LeBard, Mark McGann, Joseph B. Moon, Hari S. Muddana, Andrew Shewmaker, Jharrod LaFon, Robert W. Tolbert, A. Geoffrey Skillman, and Anthony Nicholls 25 Cloud-Native Rendering Platform and GPUs Aid Drug Discovery 617Mark Ross, Michael Drummond, Lance Westerhoff, Xavier Barbeu, Essam Metwally, Sasha Banks-Louie, Kevin Jorissen, Anup Ojah, and Ruzhu Chen 26 The Quantum Computing Paradigm 627Thomas Ehmer, Gopal Karemore, and Hans Melo Index 679

Read more less

Book SynopsisTable of Contents1. Introduction 1.1. Overview 1.2. Drugs Discovered without Rational Design 1.2.1. Medicinal Chemistry Folklore 1.2.2. Discovery of Penicillins 1.2.3. Discovery of Librium 1.2.4. Discovery of Drugs through Metabolism Studies 1.2.5. Discovery of Drugs through Clinical Observations 1.3. Overview of Modern Rational Drug Design 1.3.1. Overview of Drug Targets 1.3.2. Identification and Validation of Targets for Drug Discovery 1.3.3. Alternatives to Target-Based Drug Discovery 1.3.4. Lead Discovery 1.3.5. Lead Modification (Lead Optimization) 1.3.5.1. Potency 1.3.5.2. Selectivity 1.3.5.3. Absorption, Distribution, Metabolism, and Excretion (ADME) 1.3.5.4. Intellectual Property Position 1.3.6. Drug Development 1.3.6.1. Preclinical Development 1.3.6.2. Clinical Development (Human Clinical Trials) 1.3.6.3. Regulatory Approval to Market the Drug 1.4. Epilogue 1.5. General References 1.6. Problems References 2. Lead Discovery and Lead Modification 2.1. Lead Discovery 2.1.1. General Considerations 2.1.2. Sources of Lead Compounds 2.1.2.1. Endogenous Ligands 2.1.2.2. Other Known Ligands 2.1.2.3. Screening of Compounds 2.1.2.3.1. Sources of Compounds for Screening 2.1.2.3.1.1. Natural Products 2.1.2.3.1.2. Medicinal Chemistry Collections and Other "Handcrafted" Compounds 2.1.2.3.1.3. High-Throughput Organic Synthesis 2.1.2.3.1.3.1. Solid-Phase Library Synthesis 2.1.2.3.1.3.2. Solution-Phase Library Synthesis 2.1.2.3.1.3.3. Evolution of HTOS 2.1.2.3.2. Drug-Like, Lead-Like, and Other Desirable Properties of Compounds for Screening 2.1.2.3.3. Random Screening 2.1.2.3.4. Targeted (or Focused) Screening, Virtual Screening, and Computational Methods in Lead Discovery 2.1.2.3.4.1. Virtual Screening Database 2.1.2.3.4.2. Virtual Screening Hypothesis 2.1.2.3.5. Hit-To-Lead Process 2.1.2.3.6. Fragment-based Lead Discovery 2.2. Lead Modification 2.2.1. Identification of the Active Part: The Pharmacophore 2.2.2. Functional Group Modification 2.2.3. Structure–Activity Relationships 2.2.4. Structure Modifications to Increase Potency, Therapeutic Index, and ADME Properties 2.2.4.1. Homologation 2.2.4.2. Chain Branching 2.2.4.3. Bioisosterism 2.2.4.4. Conformational Constraints and Ring-Chain Transformations 2.2.4.5. Peptidomimetics 2.2.5. Structure Modifications to Increase Oral Bioavailability and Membrane Permeability 2.2.5.1. Electronic Effects: The Hammett Equation 2.2.5.2. Lipophilicity Effects 2.2.5.2.1. Importance of Lipophilicity 2.2.5.2.2. Measurement of Lipophilicities 2.2.5.2.3. Computer Automation of log P Determination 2.2.5.2.4. Membrane Lipophilicity 2.2.5.3. Balancing Potency of Ionizable Compounds with Lipophilicity and Oral Bioavailability 2.2.5.4. Properties that Influence Ability to Cross the Blood–Brain Barrier 2.2.5.5. Correlation of Lipophilicity with Promiscuity and Toxicity 2.2.6. Computational Methods in Lead Modification 2.2.6.1. Overview 2.2.6.2. Quantitative Structure–Activity Relationships (QSARs) 2.2.6.2.1. Historical Overview. Steric Effects: The Taft Equation and Other Equations 2.2.6.2.2. Methods Used to Correlate Physicochemical Parameters with Biological Activity 2.2.6.2.2.1. Hansch Analysis: A Linear Multiple Regression Analysis 2.2.6.2.2.2. Manual Stepwise Methods: Topliss Operational Schemes and Others 2.2.6.2.2.3. Batch Selection Methods: Batchwise Topliss Operational Scheme, Cluster Analysis, and Others 2.2.6.2.2.4. Free and Wilson or de Novo Method 2.2.6.2.2.5. Computational Methods for ADME Descriptors 2.2.6.3. Scaffold Hopping 2.2.6.4. Molecular Graphics-Based Lead Modification 2.2.7. Epilogue 2.3. General References 2.4. Problems References 3. Receptors 3.1. Introduction 3.2. Drug–Receptor Interactions 3.2.1. General Considerations 3.2.2. Important Interactions (Forces) Involved in the Drug–Receptor Complex 3.2.2.1. Covalent Bonds 3.2.2.2. Ionic (or Electrostatic) Interactions 3.2.2.3. Ion–Dipole and Dipole–Dipole Interactions 3.2.2.4. Hydrogen Bonds 3.2.2.5. Charge–Transfer Complexes 3.2.2.6. Hydrophobic Interactions 3.2.2.7. Cation–p Interaction 3.2.2.8. Halogen Bonding 3.2.2.9. van der Waals or London Dispersion Forces 3.2.2.10. Conclusion 3.2.3. Determination of Drug–Receptor Interactions 3.2.4. Theories for Drug–Receptor Interactions 3.2.4.1. Occupancy Theory 3.2.4.2. Rate Theory 3.2.4.3. Induced-Fit Theory 3.2.4.4. Macromolecular Perturbation Theory 3.2.4.5. Activation–Aggregation Theory 3.2.4.6. The Two-State (Multistate) Model of Receptor Activation 3.2.5. Topographical and Stereochemical Considerations 3.2.5.1. Spatial Arrangement of Atoms 3.2.5.2. Drug and Receptor Chirality 3.2.5.3. Diastereomers 3.2.5.4. Conformational Isomers 3.2.5.5. Atropisomers 3.2.5.6. Ring Topology 3.2.6. Case History of the Pharmacodynamically Driven Design of a Receptor Antagonist: Cimetidine 3.2.7. Case History of the Pharmacokinetically Driven Design of Suvorexant 3.3. General References 3.4. Problems References 4. Enzymes 4.1. Enzymes as Catalysts 4.1.1. What are Enzymes? 4.1.2. How do Enzymes Work? 4.1.2.1. Specificity of Enzyme-Catalyzed Reactions 4.1.2.1.1. Binding Specificity 4.1.2.1.2. Reaction Specificity 4.1.2.2. Rate Acceleration 4.2. Mechanisms of Enzyme Catalysis 4.2.1. Approximation 4.2.2. Covalent Catalysis 4.2.3. General Acid–Base Catalysis 4.2.4. Electrostatic Catalysis 4.2.5. Desolvation 4.2.6. Strain or Distortion 4.2.7. Example of the Mechanisms of Enzyme Catalysis 4.3. Coenzyme Catalysis 4.3.1. Pyridoxal 5'-Phosphate 4.3.1.1. Racemases 4.3.1.2. Decarboxylases 4.3.1.3. Aminotransferases (Formerly Transaminases) 4.3.1.4. PLP-Dependent ß-Elimination 4.3.2. Tetrahydrofolate and Pyridine Nucleotides 4.3.3. Flavin 4.3.3.1. Two-Electron (Carbanion) Mechanism 4.3.3.2. Carbanion Followed by Two One-Electron Transfers 4.3.3.3. One-Electron Mechanism 4.3.3.4. Hydride Mechanism 4.3.4. Heme 4.3.5. Adenosine Triphosphate and Coenzyme A 4.4. Enzyme Catalysis in Drug Discovery 4.4.1. Enzymatic Synthesis of Chiral Drug Intermediates 4.4.2. Enzyme Therapy 4.5. General References 4.6. Problems References 5. Enzyme Inhibition and Inactivation 5.1. Why Inhibit an Enzyme? 5.2. Reversible Enzyme Inhibitors 5.2.1. Mechanism of Reversible Inhibition 5.2.2. Selected Examples of Competitive Reversible Inhibitor Drugs 5.2.2.1. Simple Competitive Inhibition 5.2.2.1.1. Epidermal Growth Factor Receptor Tyrosine Kinase as a Target for Cancer 5.2.2.1.2. Discovery and Optimization of EGFR Inhibitors 5.2.2.2. Stabilization of an Inactive Conformation: Imatinib, an Antileukemia Drug 5.2.2.2.1. The Target: Bcr-Abl, a Constitutively Active Kinase 5.2.2.2.2. Lead Discovery and Modification 5.2.2.2.3. Binding Mode of Imatinib to Abl Kinase 5.2.2.2.4. Inhibition of Other Kinases by Imatinib 5.2.2.3. Alternative Substrate Inhibition: Sulfonamide Antibacterial Agents (Sulfa Drugs) 5.2.2.3.1. Lead Discovery 5.2.2.3.2. Lead Modification 5.2.2.3.3. Mechanism of Action 5.2.3. Transition State Analogs and Multisubstrate Analogs 5.2.3.1. Theoretical Basis 5.2.3.2. Transition State Analogs 5.2.3.2.1. Enalaprilat 5.2.3.2.2. Pentostatin 5.2.3.2.3. Forodesine and DADMe-ImmH 5.2.3.2.4. Multisubstrate Analogs 5.2.4. Slow, T ight-Binding Inhibitors 5.2.4.1. Theoretical Basis 5.2.4.2. Captopril, Enalapril, Lisinopril, and Other Antihypertensive Drugs 5.2.4.2.1. Humoral Mechanism for Hypertension 5.2.4.2.2. Lead Discovery 5.2.4.2.3. Lead Modification and Mechanism of Action 5.2.4.2.4. Dual-Acting Drugs: Dual-Acting Enzyme Inhibitors 5.2.4.3. Lovastatin (Mevinolin) and Simvastatin, Antihypercholesterolemic Drugs 5.2.4.3.1. Cholesterol and Its Effects 5.2.4.3.2. Lead Discovery 5.2.4.3.3. Mechanism of Action 5.2.4.3.4. Lead Modification 5.2.4.4. Saxagliptin, a Dipeptidyl Peptidase-4 Inhibitor and Antidiabetes Drug 5.2.5. Case History of Rational Drug Design of an Enzyme Inhibitor: Ritonavir 5.2.5.1. Lead Discovery 5.2.5.2. Lead Modification 5.3. Irreversible Enzyme Inhibitors 5.3.1. Potential of Irreversible Inhibition 5.3.2. Affinity Labeling Agents 5.3.2.1. Mechanism of Action 5.3.2.2. Selected Affinity Labeling Agents 5.3.2.2.1. Penicillins and Cephalosporins/Cephamycins 5.3.2.2.2. Aspirin 5.3.3. Mechanism-Based Enzyme Inactivators 5.3.3.1. Theoretical Aspects 5.3.3.2. Potential Advantages in Drug Design Relative to Affinity Labeling Agents 5.3.3.3. Selected Examples of Mechanism-Based Enzyme Inactivators 5.3.3.3.1. Vigabatrin, an Anticonvulsant Drug 5.3.3.3.2. Eflornithine, an Antiprotozoal Drug and Beyond 5.3.3.3.3. Tranylcypromine, an Antidepressant Drug 5.3.3.3.4. Selegiline (l-Deprenyl) and Rasagiline: Antiparkinsonian Drugs 5.3.3.3.5. 5-Fluoro-2'-deoxyuridylate, Floxuridine, and 5-Fluorouracil: Antitumor Drugs 5.4. General References 5.5. Problems References 6. DNA-Interactive Agents 6.1. Introduction 6.1.1. Basis for DNA-Interactive Drugs 6.1.2. Toxicity of DNA-Interactive Drugs 6.1.3. Combination Chemotherapy 6.1.4. Drug Interactions 6.1.5. Drug Resistance 6.2. DNA Structure and Properties 6.2.1. Basis for the Structure of DNA 6.2.2. Base Tautomerization 6.2.3. DNA Shapes 6.2.4. DNA Conformations 6.3. Classes of Drugs that Interact with DNA 6.3.1. Reversible DNA Binders 6.3.1.1. External Electrostatic Binding 6.3.1.2. Groove Binding 6.3.1.3. Intercalation and Topoisomerase-Induced DNA Damage 6.3.1.3.1. Amsacrine, an Acridine Analog 6.3.1.3.2. Dactinomycin, the Parent Actinomycin Analog 6.3.1.3.3. Doxorubicin (Adriamycin) and Daunorubicin (Daunomycin), Anthracycline Antitumor Antibiotics 6.3.1.3.4. Bis-intercalating Agents 6.3.2. DNA Alkylators 6.3.2.1. Nitrogen Mustards 6.3.2.1.1. Lead Discovery 6.3.2.1.2. Chemistry of Alkylating Agents 6.3.2.1.3. Lead Modification 6.3.2.2. Ethylenimines 6.3.2.3. Methanesulfonates 6.3.2.4. (+)-CC-1065 and Duocarmycins 6.3.2.5. Metabolically Activated Alkylating Agents 6.3.2.5.1. Nitrosoureas 6.3.2.5.2. Triazene Antitumor Drugs 6.3.2.5.3. Mitomycin C 6.3.2.5.4. Leinamycin 6.3.3. DNA Strand Breakers 6.3.3.1. Anthracycline Antitumor Antibiotics 6.3.3.2. Bleomycin 6.3.3.3. Tirapazamine 6.3.3.4. Enediyne Antitumor Antibiotics 6.3.3.4.1. Esperamicins and Calicheamicins 6.3.3.4.2. Dynemicin A 6.3.3.4.3. Neocarzinostatin (Zinostatin) 6.3.3.5. Sequence Specificity for DNA-Strand Scission 6.4. General References 6.5. Problems References 7. Drug Resistance and Drug Synergism 7.1. Drug Resistance 7.1.1. What is Drug Resistance? 7.1.2. Mechanisms of Drug Resistance 7.1.2.1. Altered Target Enzyme or Receptor 7.1.2.2. Overproduction of the Target Enzyme or Receptor 7.1.2.3. Overproduction of the Substrate or Ligand for the Target Protein 7.1.2.4. Increased Drug-Destroying Mechanisms 7.1.2.5. Decreased Prodrug-Activating Mechanism 7.1.2.6. Activation of New Pathways Circumventing the Drug Effect 7.1.2.7. Reversal of Drug Action 7.1.2.8. Altered Drug Distribution to the Site of Action 7.2. Drug Synergism (Drug Combination) 7.2.1. What is Drug Synergism? 7.2.2. Mechanisms of Drug Synergism 7.2.2.1. Inhibition of a Drug-Destroying Enzyme 7.2.2.2. Sequential Blocking 7.2.2.3. Inhibition of Targets in Different Pathways 7.2.2.4. Efflux Pump Inhibitors 7.2.2.5. Use of Multiple Drugs for the Same Target 7.3. General References 7.4. Problems References 8. Drug Metabolism 8.1. Introduction 8.2. Synthesis of Radioactive Compounds 8.3. Analytical Methods in Drug Metabolism 8.3.1. Sample Preparation 8.3.2. Separation 8.3.3. Identification 8.3.4. Quantification 8.4. Pathways for Drug Deactivation and Elimination 8.4.1. Introduction 8.4.2. Phase I Transformations 8.4.2.1. Oxidative Reactions 8.4.2.1.1. Aromatic Hydroxylation 8.4.2.1.2. Alkene Epoxidation 8.4.2.1.3. Oxidations of Carbons Adjacent to sp2 Centers 8.4.2.1.4. Oxidation at Aliphatic and Alicyclic Carbon Atoms 8.4.2.1.5. Oxidations of Carbon–Nitrogen Systems 8.4.2.1.6. Oxidations of Carbon–Oxygen Systems 8.4.2.1.7. Oxidations of Carbon–Sulfur Systems 8.4.2.1.8. Other Oxidative Reactions 8.4.2.1.9. Alcohol and Aldehyde Oxidations 8.4.2.2. Reductive Reactions 8.4.2.2.1. Carbonyl Reduction 8.4.2.2.2. Nitro Reduction 8.4.2.2.3. Azo Reduction 8.4.2.2.4. Azido Reduction 8.4.2.2.5. Tertiary Amine Oxide Reduction 8.4.2.2.6. Reductive Dehalogenation 8.4.2.3. Carboxylation Reaction 8.4.2.4. Hydrolytic Reactions 8.4.3. Phase II Transformations: Conjugation Reaction 8.4.3.1. Introduction 8.4.3.2. Glucuronic Acid Conjugation 8.4.3.3. Sulfate Conjugation 8.4.3.4. Amino Acid Conjugation 8.4.3.5. Glutathione Conjugation 8.4.3.6. Water Conjugation 8.4.3.7. Acetyl Conjugation 8.4.3.8. Fatty Acid and Cholesterol Conjugation 8.4.3.9. Methyl Conjugation 8.4.4. Toxicophores and Reactive Metabolites (RMs) 8.4.5. Hard and Soft (Antedrugs) Drugs 8.5. General References 8.6. Problems References 9. Prodrugs and Drug Delivery Systems 9.1. Enzyme Activation of Drugs 9.1.1. Utility of Prodrugs 9.1.1.1. Aqueous Solubility 9.1.1.2. Absorption and Distribution 9.1.1.3. Site Specificity 9.1.1.4. Instability 9.1.1.5. Prolonged Release 9.1.1.6. Toxicity 9.1.1.7. Poor Patient Acceptability 9.1.1.8. Formulation Problems 9.1.2. Types of Prodrugs 9.2. Mechanisms of Drug Inactivation 9.2.1. Carrier-Linked Prodrugs 9.2.1.1. Carrier Linkages for Various Functional Groups 9.2.1.1.1. Alcohols, Carboxylic Acids, and Related 9.2.1.1.2. Amines and Amidines 9.2.1.1.3. Sulfonamides 9.2.1.1.4. Carbonyl Compounds 9.2.1.2. Examples of Carrier-Linked Bipartite Prodrugs 9.2.1.2.1. Prodrugs for Increased Water Solubility 9.2.1.2.2. Prodrugs for Improved Absorption and Distribution 9.2.1.2.3. Prodrugs for Site Specificity 9.2.1.2.4. Prodrugs for Stability 9.2.1.2.5. Prodrugs for Slow and Prolonged Release 9.2.1.2.6. Prodrugs to Minimize Toxicity 9.2.1.2.7. Prodrugs to Encourage Patient Acceptance 9.2.1.2.8. Prodrugs to Eliminate Formulation Problems 9.2.1.3. Macromolecular Drug Carrier Systems 9.2.1.3.1. General Strategy 9.2.1.3.2. Synthetic Polymers 9.2.1.3.3. Poly(a-Amino Acids) 9.2.1.3.4. Other Macromolecular Supports 9.2.1.4. Tripartite Prodrugs 9.2.1.5. Mutual Prodrugs (also called Codrugs) 9.2.2. Bioprecursor Prodrugs 9.2.2.1. Origins 9.2.2.2. Proton Activation: An Abbreviated Case History of the Discovery of Omeprazole 9.2.2.3. Hydrolytic Activation 9.2.2.4. Elimination Activation 9.2.2.5. Oxidative Activation 9.2.2.5.1. N- and O-Dealkylations 9.2.2.5.2. Oxidative Deamination 9.2.2.5.3. N-Oxidation 9.2.2.5.4. S-Oxidation 9.2.2.5.5. Aromatic Hydroxylation 9.2.2.5.6. Other Oxidations 9.2.2.6. Reductive Activation 9.2.2.6.5. Nitro Reduction 9.2.2.7. Nucleotide Activation 9.2.2.8. Phosphorylation Activation 9.2.2.9. Sulfation Activation 9.2.2.10. Decarboxylation Activation 9.3. General References 9.4. Problems References Appendix Index

Read more less

Book SynopsisDrug Design and Development outlines the processes involved in the design and development of new drugs and emphasises the significance of these processes to the practice of pharmacy. The book highlights why it is important that all practicing pharmacists, including those working in hospitals or high street stores, have a solid understanding of the process of the design and development of the drugs they interact with. It adopts an integrated approach, formulated to complement courses which are designed in line with the General Pharmaceutical Council''s new curriculum requirements. Furthermore, this is the only integrated textbook to consider both drug design and development within one volume. Throughout the book, the journey of the drug, from discovery to market, is presented in an integrated fashion, emphasising the interconnection of all the processes involved.Trade ReviewWell written text that guides students through the complex elements of the drug development process. It has a chemistry focus and utilises 'key points' to reinforce the important aspects at regular opportunities. * Dr James F. Brown, University of Portsmouth *Table of Contents1: Introduction Part 1 Drug targets 2: Receptors and signal transduction 3: Enzymes as drug targets 4: Nucleic acids and protein synthesis as drug targets 5: Other drug targets Part 2 Origins of drug molecules 6: Sources of lead compounds 7: Drug synthesis 8: Optimisation of lead compounds 9: Computer-aided drug design 10: Combinatorial chemistry and high-throughput screening 11: Biotechnology and biopharmaceuticals Part 3 Biological aspects of drug development 12: Drug metabolism 13: Pharmacogenetics and pharmacogenomics 14: Toxicity testing Part 4 Preformulation studies 15: Solubility and drug development 16: Solid state characteristics 17: Drug stability Part 5 Clinical research 18: Clinical research and its regulation 19: Design and management of clinical trials

Read more less

Book SynopsisIn this book we present recent studies that have been carried out on some widely used medicinal plants. The need for new and alternative treatments stem from the lack of efficiency of existing remedies for certain illnesses. We have compiled information that may be useful to researchers in their quest to develop new drugs.Table of ContentsPart 1: Ethnobotany 1. The Genus Aloysia Paláu (Verbenaceae) in Argentina. A Paradigm in Ethnobotany 2. Ethnobotany of Medicinal and Sacred Plants with Ethnopharmacological Potential from Southwestern Colombia 3. Ethnobotanical Uses and Potential Pharmaceutical Applications of the Cactaceae Family 4. Traditional Use of Plants in Mexico for the Treatment of Diabetes: An Ethnopharmacological Review and Scientific Evaluations 5. Limits and Risks of Plants Valorization in Morocco Associated with Their Vernacular Names 6. Resilience of Mapuche Health System and the Influence of COVID-19 Part 2: Traditional Knowledge of Useful Plants 7. Medicinal Use of the Plants of the Atacama Desert 8. Local Botanical Knowledge of Plants Associated with Andean and Chinese Traditions in the Metropolitan Area of Buenos Aires (Argentina): An Urban Ethnobotany Study 9. Traditional Uses, Phytochemistry, and Pharmacology of Mopane (Colophospermum mopane) in Southern African Countries 10. Traditional Medicine of the Kichwa of the Upper Napo 11. Traditional Practices Regarding the Use of Botanicals to Treat Bovine Haemonchosis in Pakistan

Read more less

Book SynopsisHerbal Treatment of Anxiety: Clinical Studies in Western, Chinese and Ayurvedic Traditions explains the nature and types of anxiety, its neurobiology, the pathophysiology that exacerbates and perpetuates it, and the psychopharmacology of the chemical agents that relieve its manifestations. Throughout the text are discussions of Western, Chinese and Ayurvedic herbal treatments that have been clinically shown to be effective in relieving anxiety. The book also features a scientific discussion of the use of herbs and essential oils in aromatherapy and the mechanisms by which they may work. The book concludes by providing bases upon which herbs can be chosen to treat the anxiety of patients according to their individual needs.Additional features include: Examines the increasingly popular subject of the use of herbs as a natural alternative treatment and provides a much-needed scientific basis for treatments often considered as merely folk medicine. Discusses the psychoactive phytochemicals contained in herbs. Includes a chapter discussing the nature and mechanisms of action of adaptogens. Adds to the armamentarium of anxiolytics for providers who have become reluctant to prescribe benzodiazepines as treatment of anxiety, particularly in the context of the opiate crisis. Gives an introduction to herbal treatments of traditional Chinese and Ayurvedic medicine. Offers practical advice on initiating and managing herbal treatments. Herbal Treatment of Anxiety is a valuable reference for psychiatrists, psychiatric nurse practitioners, primary care providers, naturopathic doctors and therapists interested in the most current scientific information on the effects of herbal treatments of anxiety disorders.

Read more less

Book SynopsisThe application of computational modeling and simulation has extended beyond PK/PD prediction of clinical trial outcomes, by defining regulatory strategy as well as optimization of therapeutic candidates. Further, regulatory agencies are accepting modeling and simulations for approval in special populations, drug-drug interactions, and dosing regimen changes. This volume provides a comprehensive coverage of drug design, chemoinformatics, molecular modeling, and computer-aided formulation development. Computer simulations play a crucial role in the pharmaceutical industry, accelerating drug discovery and development by predicting drug behavior, optimizing systems, so reducing the need for animal testing.Key Features Illustrates how computer simulations play a crucial role in the pharmaceutical industry, accelerating drug discovery and development. PK/PD simulations play a crucial role in optimizing dosing regimens and understanding the time course of drug effects. Depicts the role of computers in drug research development both in clinical and preclinical stage by citing examples of approved FDA drugs. Provides case studies detailing the step by step process for using software such as Python for programming in pharmaceutical industry; Gromacs, Data warrior, Autodock and Biovia. Discusses how artificial intelligence and machine learning can be used to optimize and refine simulation models.

Read more less

Book SynopsisThis book series explores the intersection of phytotherapy and personalized medicine. It addresses the scientific foundations, clinical applications, and emerging technologies related to the use of natural products in precision healthcare. Each volume in the series is peer-reviewed and structured to support postgraduate education, research, and global academic engagement.Key Features Explores the origin, core concepts, and significance of personalized medicine, emphasizing its evolution in modern healthcare. Highlights how natural compounds contribute to drug development and their growing role in integrative, personalized treatment. Examines how genetic variations influence individual responses to natural products, shaping personalized phytotherapy. Discusses biomarkers used to predict, diagnose, and monitor therapy effectiveness when using natural products. Explores how natural compounds can modulate gene expression without altering DNA, offering targeted treatment options.

Read more less

Book SynopsisGood Manufacturing Practice (GMP) ensures medicinal products are produced consistently and controlled to the quality standards appropriate for their intended use and as required by product specifications or marketing authorization. Annex 11 details the European Medicines Agency (EMA) GMP requirements for computer systems.The purpose of Annex 11 is to provide the EMA healthcare industry with consistent criteria for effective implementation, control, and use of computer systems. EU Annex 11 Guide to Computer Validation Compliance for the Worldwide Health Agency GMP supplies practical information to facilitate compliance with computer system GMP requirements, while highlighting and integrating the Annex 11 guidelines into the computer compliance program.The ideas presented in this book are based on the author's 25 years of experience with computer validation in the healthcare industry with various computer systems development, maintenance, and quality functiTable of ContentsIntroduction. SLC, Computer Validation, and Annex 11. Annex 11 Principles. Risk Management. Personnel. Suppliers and Service Providers. Validation. Data. Accuracy Checks. Data Storage. Printouts. Audit Trails—Ensuring Data Integrity. Change and Configuration Management. Periodic Evaluation: Independent Review to Ensure Continued Validation of Computerized Systems. Security. Incident Management. Electronic Signatures: Electronic Signing Requirements. Batch Certification and Release. Business Continuity. Archiving. SLC Documentation. Relevant Procedural Controls. Maintaining the Validated State in Computer Systems. Annex 11 and the Cloud. EU GMP Chapter 4–Documentation and Annex 11. Annex 11 and Electronic Records Integrity. Annex 11 and 21 CFR Part 11: Comparisons for International Compliance.

Read more less

Book SynopsisOrganic chemistry plays a vital role in the pharmaceutical industry. Knowledge of organic compounds is used to inform research and further the discovery and development of new medicines. Likewise, organic chemistry is fundamental to understanding biological reactions, mechanisms and all life sciences in general. Basic Chemistry for Life Science Students and Professionals is an ideal introduction to organic chemistry in the context of the life sciences and pharmacy related disciplines; utilising drug molecules to illustrate the chemical basis of their efficacy and interaction with biological targets. This book builds upon the basic concepts of organic chemistry to develop the reader’s understanding of the importance of organic chemistry to the life sciences from natural product sources, their synthesis, and approaches to drug discovery. Ideal for undergraduate students in the natural sciences, this book is also an excellent primer for postgraduates in a variety of disciplines including forensic science and allied-health programmes as well as professionals working in related fields seeking a comprehensive introduction to organic chemistry in the context of pharmaceuticals.Table of ContentsIntroduction to Organic Compounds and Covalent Bonding; Polarity of Bonds, Electronegativity, and Intermolecular Forces; Types of Organic Compounds, Nomenclature, and Basic Reactions: Alkanes and Cycloalkanes; Types of Organic Compounds, Nomenclature, and Basic Reactions: Alkenes, Cycloalkenes and Other Unsaturated Hydrocarbons; 5 Types of Organic Compounds, Nomenclature, and Basic Reactions: Functional Groups; Isomerism in Organic Compounds and Drug Molecules: Chemistry and Significance in Biology; Organic Macromolecules in Cellular Structures, Metabolism, and as Drugs: From Amino Acids to Proteins; Organic Macromolecules in Cellular Structures, Metabolism, and as Drugs: From Monosaccharides to Complex Carbohydrates; Organic Macromolecules in Cellular Structures, Metabolism, and as Drugs: From Fatty Acids to Complex Lipids and Fat; Organic Macromolecules in Cellular Structures, Metabolism, and as Drugs: From Nucleotides to Nucleic Acids; Physicochemical Properties of Organic Compounds and Drug Molecules; Drug-Target Interactions; Structural Diversity and Sources of Drugs: From Nature to Synthetic and Recombinant DNA Technology

Read more less

Book SynopsisTable of Contents1. Introduction 2. Polysorbate Surfactants used in biopharmaceuticals: An overview including in vivo fate and toxicology perspective 3. Surfactants (polysorbate and poloxamer) synthesis and degradation: Overview and relevance 4. Mechanisms of stabilization of proteins by surfactants 5. Behaviour of surfactant during processing (UF/DF, filter adsorption) 6. Analytical methods for surfactant characterization in Drug Product 7. Oxidative degradation of surfactants: Mechanisms 8. Hydrolytic degradation of surfactants and impact on protein stabilization 9. Regulatory Perspective on Surfactant Monitoring and Control 10. Control strategies to address surfactant degradation: A quality perspective 11. A look to the future - closing remarks

Read more less

Book SynopsisMicrobiologists working in both the pharmaceutical and medical device industries, face considerable challenges in keeping abreast of the myriad microbiological references available to them, and the continuously evolving regulatory requirements. The Handbook of Microbiological Quality Control provides a unique distillation of such material, by providing a wealth of microbiological information not only on the practical issues facing the company microbiologist today, but also the underlying principles of microbiological quality assurance. All the chapters have been written by leading experts in this field. The Handbook of Microbiological Quality Control provides guidance on safe microbiological practices, including laboratory design and sampling techniques. The design storage, use and quality control of microbiological culture is considered in depth. Principles of enumeration and identification of micro-organisms, using both traditional and rapid methods as well as the pharmacopoeial methTable of ContentsSafety in Microbiology. Culture Media. Sampling. Enumeration of Micro-organisms. Identification of Micro-organisms. Specified Organisms. Rapid Methods. Sterility Assurance. Endotoxin Testing. Preservative Efficacy Testing. Microbiological Assay. Disinfection and Cleansing. Microbiological Audit. Case Studies and Calculations.

Read more less

Book SynopsisFocusing on the management of healthcare related biotechnology, this text is a practical guide assisting all healthcare related biotech professionals in their day-to-day activities. It contains chapters on bioeconomy, biolicensing, biofinance, biopartnering, biodrug research, biomarket planning, biopromotion, product life cycle management, and bTable of ContentsThe Healthcare Biotechnology Industry: Bioeconomy. Intellectual Property: Intellectual Property Management. Biolicensing. Funding: Biofinance. Biopartnering. New Product Development: Biodrug Research. Biomanufacturing. Marketing: Biomarketing planning. Biopromotion. Biopricing. Biosupply Chain. Product Life Cycle Management. Running the Business: Biobusiness models. Biosimilars Model. Biocompany Life Cycle.

Read more less

Book SynopsisThere is a dramatic rise of novel drug use due to the increased popularity of so-called designer drugs. These synthetic drugs can be illegal in some countries, but legal in others and novel compounds unknown to drug chemistry emerge monthly. This thoughtfully constructed edited reference presents the main chromatographic methodologies and strategies used to discover and analyze novel designer drugs contained in diverse biological materials. The methods are based on molecular characteristics of the drugs belonging to each individual class of compounds, so it will be clear how the current methods are adaptable to future new drugs that appear in the market.Table of ContentsIntroduction. Designer Drugs: Legislating for Tomorrow Through the Use of Class Definitions and Pharmacophore Principles. Alternative Legislation with Designer Drugs. Biological Precursors of Designer Drugs. Liquid Chromatography – Mass Spectrometry in Analysis of Designer Drugs. Ambient Plasma Ionization Techniques in Forensic Analysis. Application of LC-QTOFMS for the Identification of the Structure of New Psychoactive Substances. Rapid Generation of Metabolites by Electrochemical Method. Gas Chromatography – Mass Spectrometry in Analysis of Designer Drugs. NMR Spectroscopy in the Analysis of Designer Drugs. Preparation of Biological Material for Toxicological Analysis. Discrimination among the Designer Drug Isomers by Chromatographic and Spectrometric Methods. Liquid Chromatography-Mass Spectrometry and Ambient Mass Spectrometry Applied to the Analysis of Synthetic Cannabinoids. Cathinone Derivatives and Their Analysis. NBOMe Derivatives of Phenylethylamines and Their Analysis. 2C Derivatives of Phenylethylamines and Their Analysis. Modern Techniques for the Analysis of Piperazines. Fenantyl Analogues and Their Analysis. Modern Techniques for the Identification of Tryptamines. Toxicological Analysis of New Opioids. Toxicological Analysis of Designer Benzodiazepines. Thin-layer Chromatography in the Analysis of Designer Drugs

Read more less

Book SynopsisRevised to reflect significant advances in pharmaceutical production and regulatory expectations, Handbook of Validation in Pharmaceutical Processes, Fourth Edition examines and blueprints every step of the validation process needed to remain compliant and competitive. This book blends the use of theoretical knowledge with recent technological advancements to achieve applied practical solutions. As the industry's leading source for validation of sterile pharmaceutical processes for more than 10 years, this greatly expanded work is a comprehensive analysis of all the fundamental elements of pharmaceutical and bio-pharmaceutical production processes. Handbook of Validation in Pharmaceutical Processes, Fourth Edition is essential for all global health care manufacturers and pharmaceutical industry professionals.Key Features: Provides an in-depth discussion of recent advances in sterilization Identifies obstacles tTable of Contents1. Why Validation?, 2. Facility Design for Validation, 3. Modular Facilities – Meeting the Need for Flexibility, 4. Commissioning and Qualification, 5. Design & Quaification of Controlled Environments, 6. Validation of Pharmaceutical Water Systems, 7. Validation of Critical Utilities, 8. Calibration and Metrology, 9. Risk Management and Thermal Validation, 10. Change Control, 11. MICROBIOLOGY OF STERILIZATION PROCESSES, 12. Biological Indicators, 13. Steam Sterilization in Autoclaves, 14. Validation of Terminal Sterilization, 15. Steam Sterilization-in-Place Technology and Validation, 16. Dry Heat Sterilization, 17. Depyrogenation by Inactivation and Removal, 18. Ethylene Oxide Sterilization, 19. Validation of chlorine dioxide Sterilization, 20. Liquid Phase Sterilization, 21. Vapor Sterilization and Decontamination, 22. Validation of the Radiation Sterilization of Pharmaceuticals, 23. Validation of Sterilizing Grade Filters, 24. Disinfecting Agents: The Art of Disinfection, 25. Cleaning and Disinfecting Laminar Flow Workstations, Bio Safety Cabinets and Fume Hoods, 26. Contamination Control for Component Introduction to Classified Areas, 27. Aseptic Processing for Dosage Form Manufacture, 28. Validation of Manual Aseptic Processes, 29. Validation of Aseptic Processing for Bulk Pharmaceutical Chemicals, 30. Qualification and Validation of Advanced Aseptic Processing Technologies, 31. Total Particle Monitoring, 32. Environmental Monitoring, 33. Validation of Container Component Preparation, 34. Validation of Lyophilization, 35. Validation of Packaging Processes for Sterile Products, 36. Validation of Active Pharmaceutical Ingredients, 37. Cell Culture Process Validation including Cell Bank Qualification, 38. Validation of Recovery and Purification Processes, 39. Validation of Process Chromatography, 40. Single Use Technologies and Systems, 41. Considerations for Process Validation for Cell and Gene Therapies, 42. Validation of Solid Dosage Forms, 43. Validation of Validation of Oral / Topical Liquids & Semi-Solids, 44. Validation of Non-Sterile Packaging Operations, 45. Validation of Cleaning Processes, 46. Validation of Training, 47. Vendor Qualification and Validation, 48. Validation of Clinical Trial Manufacturing, 49. Validation of New Products, 50. Retrospective / Continuous Process Validation, 51. Validation & 6 Sigma, 52. Validation and Contract Manufacturing, 53. Computerized Systems Validation, 54. Risk Based Validation of Laboratory Information Management Systems, 55. Control Systems Validation, 56. Process Analytical Technology and Validation, 57. Validation of Analytical Procedures and Physical Methods, 58. Validation of Microbial Methods, 59. "Rapid Methods for Aseptic Processing and Their Validation", 60. Extractables and Leachables in Drug Products: An Overview, 61. Evolution and Implementation of Validation in the United States, 62. Validation in Europe - What are the Differences?, 63. Japanese Approach to Validation, 64. Organization of Validation in a MultiNational Pharmaceutical Company, 65. Validation in a Small Pharmaceutical Company, 66. Regulatory Aspects of Process Validation in the United States, 67. The Future of Validation

Read more less

Book SynopsisWhat defines a quality lead, where these quality leads come from and how one discovers them has been the subject of intense debate within the pharmaceutical industry. This volume addresses these questions and discusses diabetes, obesity and tuberculosis. It presents research in the field of drug discovery.Table of ContentsPreface List of Contributors Hit and Lead Identification: Efficient practices for drug discovery DPPIV Inhibition: Promising Therapy for the Treatment of Type 2 Diabetes Recent Progress Towards Nonpeptide Ligands for the Melanocortin-4 Receptor Tuberculosis chemotherapy: recent developments and future perspectives Subject Index Author Index (Volumes 1-45) Subject Index (Volumes 1-45)

Read more less

Book SynopsisThis text is aimed at potential clinical investigators usually physicians, especialy those thinking about doing clinical trials to evaluate new drugs - mostly sponsored by pharmaceutical companies.Table of ContentsIn this book a respected clinical investigator shares his experiences and insights, so that others can share in the excitement of clinical research while avoiding some of the pitfalls that inevitably beset the clinical trialist. This book provides practical advice on how to interact with various ...monitors..., auditors, and project leaders running a trial. It also gives advice on how to recruit patients to the trials. The author examines subjects such as allocation of time, space, and staff. This book is predominantly aimed at doctors performing clinical trials for pharmaceutical companies and will be of great help to Heads of Clinical Research in pharmaceutical companies--also to academic staff in university clinical departments, particularly pharmacology.

Read more less

Book SynopsisThe drug discovery and development process is getting longer, more expensive, and no better. The industry suffers from the same clinical attrition and safety-related market withdrawal rates today as it did 20 years ago. Industrialization of Drug Discovery: From Target Selection Through Lead Optimization scrutinizes these problems in detail, contrasting the promise of technology and industrialization with the challenges of using the tools available to their best advantage. The book explores early successes, examines the current state of the art, and provides a strategic analysis of the issues currently facing drug discovery.Introducing the historical background and current status of the industry, the book delineates the basic tenets underlying modern drug discovery, how they have evolved, and their use in various approaches and strategies. It examines, in detail, the regulations, requirements, guidelines, and draft documents that guide so many FDA actions. The editor devotes the remainder of the discussion to industrialization, compound and knowledge management functions, the drug screening process, collaboration, and finally, ethical issues. Drawing on real-life, from-the-trenches examples, the book elucidates a new approach to drug discovery and development. This modern-day, back-to-basics approach includes three steps: understand the science, unravel the story, and then intelligently apply the technology, bringing to bear the entire armamentarium of industrialization techniques, not just automation, to the discovery process. Using these steps, you can meet the goals of more specific targets, more selective compounds, and decreased cycle times. In effect, you can look for a bigger needle in a smaller haystack. Daniel E. Levy, editor of the Drug Discovery Series, is the founder of DEL BioPharma, a consulting service for drug discovery programs. He also maintains a blog that explores organic chemistry.Trade Review“The book comprises of 10 well-defined chapters. Detailed discussion on historical background to drug discovery in modern age consists of basic concepts, how they have evolved and various approaches and strategies in modern drug discovery. … The book provides a very good review on all aspects of industrialization of drug discovery. … the book is of particular interest since it gives a systematic and in depth account of related topics to transform research into industrialization. This is a very good book of relevance to anyone interested in drug discovery and more, so for all personnel working in drug discovery.” —K. S. Laddha, Reader in Pharmacognosy, University Institute of Chemical Technology, Mumbai, in Chemical Industry Digest, February 2007"Chapter 4, the best part of the book, is an extensive and excellent discussion of aspects of compound- library management. The authors of this chapter have considered all basic aspects of this important component of drug discovery . . . well written with extensive references." – Robert Goodnow, Hoffmann-LaRoche, in ChemMedChem, 2006, No. 3Table of ContentsDrug Discovery in the Modern Age: How We Got Here and Where Do We Go?. The Regulatory Age. Industrialization Not Automation. Compound Management. High Throughput Screening. Parallel Lead Optimization. Knowledge Management. ROI – How to Measure It? How to Get It?. Collaboration in a Virtual and Global Environment. From Genome to Drug: Ethical Issues.

Read more less

Book SynopsisExploring how to apply in vitro/in vivo correlations for controlled release dosage forms, Bioavailability of Drug Delivery Systems: Mathematical Modeling clearly elucidates this complex phenomena and provides a guide for the respective mathematical modeling. The book introduces mathematical modeling methods for calculating the profiles of plasma levels obtained with controlled release dosage forms and provides examples and case studies to illustrate the techniques employed. The author has considerable experience in investigating mathematical fundamentals that are related to pharmaco- and toxicokinetics, modified-release drug products, physiologic pharmacokinetics and statistical treatment in clinical situations. The mathematical models he has developed are particularly powerful because they account for such major parameters as the kinetics of drug release controlled by diffusion or by erosion, and the kinetics of absorption into and elimination out of the plasma. They are alTrade Review"…it adds new perspectives on topics…[and] gives an overview of the theoretical and experimental work of its senior author."-European Journal of Pharmaceutics and BiopharmaceuticsTable of ContentsDefinitions. Intravenous Administration. Oral Dosage Forms With Immediate Release. Kinetics of Drug Release From Oral Sustained Dosage Forms. Bibliography on In Vitro/In Vivo Correlations. Plasma Drug Level With Diffusion-Controlled Dosage Forms. Plasma Drug Level With Erosion-Controlled Dosage Forms. Effect of Non-Compliance on the Plasma Drug Level. Drug Transfer in Various Tissues. Process of Transdermal Drug Transfer.

Read more less

Book SynopsisThis unique reference set provides a broad-based, in-depth presentation on angiotensin II receptors, from the genes that encode them to the responses they mediate in humans. The books emphasize known and potential therapeutic applications of the antagonists of angiotensin II receptors and the angiotensin-converting enzyme inhibitors. The molecular biology of angiotensin II receptors is reviewed, as are the biochemical effects mediated by angiotensin II receptors. This is the first publication to analyze in detail the structure-activity relationships for both peptide and nonpeptide angiotensin II receptor agonists and antagonists. It also presents the pharmacological effects mediated by angiotensin II receptors both in the periphery and in the brain.Table of ContentsIntroduction: Medicinal Chemistry of Angiotensin II Receptors, J. Gleason and R.R. Ruffolo, Jr.Structure-Activity Relationships of Peptide Angiotensin II Receptor Agonists and Antagonists, J. Samanen and D. RegoliConformational Models of Angiotensin II for Nonpeptide Antagonist Design, J. Samanen, J. Hempel, R. Keenan, C. Peishoff, and J. WeinstockStructure Activity Relationships of Nonpeptide Angiotensin II Receptor Antagonists, J. Weinstock and R.M. KeenanIndex

Read more less

Book SynopsisSetting up a GXP environment where none existed previously is a very daunting task. Getting staff to write down what they do for every task is a correspondingly difficult and time-consuming exercise. Examining how to maintain quality control in clinical trial research, A Practical Guide to Quality Management in Clinical Trial Research provides a cornerstone of knowledge for establishing a quality system that complies with the relevant regulations. There are many books available that cover how to interpret regulations. Going a step or two further, this book provides practical advice that is useful on a daily basis.The book contains information for various standards including GLPs, GCPs, and GMPs. It gives detailed explanations of how to prepare, update, and maintain SOPs and includes advice on training and development of personnel. Drawing directly on his years of experience, the author delineates a from-the-trenches methodology that creates a value-added quality management system from a business perspective. He provides a solid foundation as well as tips and techniques for establishing a quality system that will comply with all the relevant regulations. The author's integrated approach and anecdotal style turns technically accurate information into easy reading. The book arms you with tools and concepts that you can use to go beyond regulatory compliance and move into the realm of business quality improvement.Trade Review"…provides the reader with a pragmatic approach to the principles governing accepted methodologies within the working environment and provides some useful examples of these interpretational differences across industry."-Quasar"…provides a solid foundation as well as tips and techniques for establishing a quality system that will comply with all the relevant regulations."--Anticancer ResearchTable of ContentsIn the Beginning There Was GLP. Before GCP. Training in the Regulated Environment. Computing in the Regulated Environment. QA Activity. Beyond Compliance. Business Improvement. A Summary. Appendix: Information Resources and Acronyms.

Read more less

Book SynopsisThe use of medicinal plants in herbal and modern medicine has gained popularity over the last few decades due to consumers taking more natural approaches to medicine. Aquatic medicinal plants are rich in bioactive compounds and demonstrate various commercial, nutraceutical, and biological applications. Aquatic Medicinal Plants offers the reader a wealth of information on uses of bioactive components of these plants, along with crucial references, and explains their traditional uses, phytochemistry, and pharmacological properties.Features Provides information on aquatic and semiaquatic medicinal plants and their uses globally. Discusses phytochemical components with the known active constituents and their pharmaceutical applications. This volume in the Exploring Medicinal Plants series is appropriate for scientists, experts, and consultants associated with the exploration of aquatic medicinal plant usage.  This book is an essenTable of ContentsMedicinal Importance of Nelumbo nucifera. Traditional Uses, Important Phytochemical, and Therapeutic Profile of Persicaria hydropiper. Ethnobotanical, Phytochemistry, and Pharmacological Activity of Marsilea minuta. Traditional Uses, Phytochemistry, and Pharmacological Properties of Hedychium coronarium. Pharmacognostical Phytochemical, and Ethnomedicinal Properties of Enhydra fluctuans. Medicinal Uses and Pharmacological Properties of Acorus calamus. Medicinal properties of Rotula aquatic. Traditional Uses and Pharmacological Profile of Sphaeranthus indicus. Phytochemistry and Medicinal Uses of Pistia stratiotes. Biological Activity and Medicinal Uses of Arundo donax. Sagittaria sagittifolia. Phytochemistry and Pharmaceutical Application of Laurencia obtuse: A Red Seaweed. Phytochemical and Therapeutic Properties of Didemnum genus. Brown Algae (Phaeophyta) Source of Different Phytochemical and their Medicinal Application. Phytochemistry and Bioactivity of Green Algae (Chlorophyta). Chemical Composition and Biological Activity of Red Algae (Rhodophyta).

Read more less

a huge range and FREE tracked UK delivery on ALL orders.

Read more less

Book SynopsisThis volume in the popular series, Drugs and the Pharmaceutical Sciences, begins with the history of cancer treatment, carcinogens, and molecular mechanisms involved in cancer pathogenesis. It incudes conventional and advanced cancer therapies ranging from oral and parenteral preparations to advanced fabricated systems such as nanoparticles, liposomes, antibodies, aptamers, poly(amidoamine) and photodynamic therapies. The preparation and mechanisms of molecular targeting of cancer are presented and the authors focus on a diverse audience including undergraduates and research students.Features Timely coverage of changes in process control technology for the phamaceutical industry, a dynamic area in terms of products and manufacturing processes Provides an update on the unique requirements of these industries and how they differ from others, for example the microelectronics or specialized chemicals industries Draws on the author''s vaTable of Contents History of Cancer Therapies Cancer and Carcinogens Causes of Death from Cancer Passive Targeting Cancer Active Targeting Strategies Conventional Cancer Therapies Oral Anticancer Therapies Parenteral Anticancer Therapies Advanced Cancer Therapies The Advent of Micro and Nano-spheres for Cancer Treatment The Emergence of Liposomes in Cancer Therapy Niosomes-Based Anticancer Therapies Solid Lipid Nanoparticles-Based Anticancer Therapies Mesoporous Nanoparticles-Based Anticancer Therapies Antibody-Based Cancer Therapies Aptamer-Based Anticancer Therapies Polyamidoamines-Based Anticancer Therapies Photodynamic Therapies for Cancer Treatment

Read more less

Book SynopsisMedical Affairs is one of the three strategic pillars of the pharmaceutical and MedTech industries, but while clear career paths exist for Commercial and Research and Development, there is no formal training structure for Medical Affairs professionals. Medical and scientific expertise is a prerequisite for entry into the function, and many people transitioning into Medical Affairs have advanced degrees such as PhD, MD, or PharmD. However, these clinical/scientific experts may not be especially well-versed in aspects of industry such as the drug development lifecycle, crossfunctional collaborations within industry, and digital tools that are transforming the ways Medical Affairs generates and disseminates knowledge. This primer for aspiring and early-career Medical Affairs professionals equips readers with the baseline skills and understanding to excel across roles.Features:Defines the purpose and value of Medical Affairs and provides clear career Table of ContentsSECTION 1: MEDICAL AFFAIRS IN THE PHARMACEUTICAL AND MEDTECH INDUSTRIES Chapter 1 What Is Medical Affairs? Chapter 2 Groups and Structure of Medical Affairs Chapter 3 Medical Affairs Collaborations Across the Drug/Device Development Lifecycle Chapter 4 Measuring the Impact of Medical Affairs Chapter 5 Medical Affairs Careers SECTION 2: THE PRACTICE OF MEDICAL AFFAIRS Chapter 6 Medical Strategy and Launch Excellence Chapter 7 Evidence Generation and Real-World Evidence Chapter 8 Medical Communications Chapter 9 External Education Chapter 10 Field Medical Chapter 11 Insights Chapter 12 Medical Information Chapter 13 Patient Centricity Chapter 14 Medical Operations Chapter 15 Digital Strategy Chapter 16 Compliance Chapter 17 Rare Disease and Gene Therapy Chapter 18 Medical Affairs in MedTech

Read more less

Book SynopsisThe management of clinical data, from its collection during a trial to its extraction for analysis, has become critical in preparing a regulatory submission and obtaining approval to market a treatment. Groundbreaking on its initial publication nearly 14 years ago, and evolving with the field in each iteration since then, this latest volume includes revisions to all chapters to reflect the recent updates to ICH E6, good clinical practices, electronic data capture, and interactive response technologies. Keeping the coverage practical, the author focuses on the most critical information that impacts clinical trial conduct, providing a full end-to-end overview for clinical data managers.Features:Provides an introduction and background information for the spectrum of clinical data management tasks.                            &nbsp

Read more less

a huge range and FREE tracked UK delivery on ALL orders.

Read more less

a huge range and FREE tracked UK delivery on ALL orders.

Read more less

Book SynopsisLeadership in the Pharmaceutical Industry focuses on leadership in pharmaceutical organisations at three levels: individual, team, and organisational. At the individual level, it covers leadership basics, theories, types of leaders, differences between leader and manager, leadership traits and skills, and systems thinking. At the team level, it explores leadership styles, the leader's interaction with the team, and employee motivation, including the use of intrinsic motivational factors. At the organisational level, it examines the leader's role in creating and maintaining organisational culture, forming and implementing organisational strategy, and managing organisational changes.The book also addresses the specifics of the pharmaceutical industry, including the types and characteristics of innovations and the ethics of leader behaviour, emphasising the importance of ethical leadership. Notably, leadership issues are illustrated with practical cases featuring prominent leaders such as Paul Janssen, Daniel Vasella, Charles Walgreen III, John C. Martin, Roy Vagelos, Albert Bourla, Kiran Mazumdar-Shaw, and Filya Zhebrovska. These leaders were or are involved in creating, manufacturing, and providing patients with pharmaceutical products.The book is designed to benefit readers from various business sectors, with the primary audience being academics, students, and individuals interested in leadership in the pharmaceutical industry.

Read more less

Book SynopsisProvides a comprehensive, practical guide to breaking into and excelling in Medical Science Liaison (MSL) rolesâone of the pharmaceutical industry's most strategically important yet misunderstood positions. Through patient impact stories, actionable frameworks, and insider insights, this book transforms the daunting MSL job search into a strategic, relationship-driven process while preparing readers for long-term career success.Key Features Unique Positioning: Treats MSL job search as relationship-building preparation for actual role success Practical Depth: Moves beyond generic advice to provide specific frameworks, templates, and industry insider knowledge Future Proofing: Integrates AI revolution in medical affairsâa topic absent from existing materials Authentic Voice: Written by practicing MSL with demonstrated success across multiple therapeutic areas and organizations Patient-Impact Focus: Grounds career advice in meaningful healthcare outcomes rather than purely transactional objectives

Read more less

Book SynopsisOligonucleotides represent one of the most significant pharmaceutical breakthroughs in recent years, showing great promise as diagnostic and therapeutic agents for malignant tumors, cardiovascular disease, diabetes, viral infections, and many other degenerative disorders. The Handbook of Analysis of Oligonucleotides and Related Products is an essential reference manual on the practical application of modern and emerging analytical techniques for the analysis of this unique class of compounds. A strong collaboration among thirty leading analytical scientists from around the world, the book provides readers with a comprehensive overview of the most commonly used analytical techniques and their advantages and limitations in assuring the identity, purity, quality, and strength of an oligonucleotide intended for therapeutic use.Topics discussed include: Strategies for enzymatic or chemical degradation of chemically modified oligonucleotides toTrade ReviewThis is a unique resource for guiding the analysis of oligonucleotide-based drug products. No other single source provides such a comprehensive overview of the necessary analytical techniques that assess the qualitative characteristics of oligonucleotides intended for pharmaceutical use.—Rachel R Chennault, Ph.D.(American College of Clinical Pharmacy), in Doody's Notes Table of ContentsPurity Analysis and Impurities Determination by Reversed-Phase High- Performance Liquid Chromatography. Purity Analysis and Impurities Determination by AEX-HPLC. Purity Analysis and Molecular Weight Determination by Size Exclusion HPLC Analysis. Analysis of Oligonucleotides by Liquid Chromatography—Mass Spectrometry. Sequence Determination and Confirmation by MS/M S and MALDI-TOF. Tm Analysis of Oligonucleotides. Purity and Content Analysis of Oligonucleotides by Capillary Gel Electrophoresis. Bioanalysis of Therapeutic Oligonucleotides Using Hybridization-Based Immunoassay Techniques. Oligonucleotide Assay and Potency. Microbial Analysis: Endotoxin Testing. Analysis of Residual Solvents by Head Space Gas Chromatography. Determination of Extinction Coefficient. Structural Determination by NMR. Infrared Analysis of Oligonucleotides. Stability Indicating Methods for Oligonucleotide Products. Analysis by Hydrophilic Interaction Chromatography. Determination of Base Composition. Analysis of Metals in Oligonucleotides. Regulatory Considerations for the Development of Oligonucleotide Therapeutics.

Read more less

Book SynopsisRegulatory bodies such as the European Medicine Agency have done tremendous work in collaboration with experts from the field to develop Good Clinical Practices that apply not only in Europe but also in emerging countries. Designed to be a teaching aid and reference guide, A Practical Guide to Human Research and Clinical focuses on ethics, regulations, and guidelines.Conducting a successful clinical trial requires not only a strong basic knowledge, but also hands-on practical training. The book explains the intricate details of the subject to readers by citing concrete cases, exercises, and templates along with the theoretical aspects. Prof. M.U.R Naidu and his co-authors address all aspects of clinical trials from clinical research, drug development, and quality to methodology, biostatistics, and pharmacovigilance.Table of ContentsClinical Research – A Clinical Investigator’s PerspectiveIntroduction Scientific and Practical Aspects Financial ConsiderationsMedical Device Development, Process and RegulationIntroduction Categories of Medical Devices Evaluation of Medical Devices Regulatory Process Pre-Clinical Drug DevelopmentIntroduction Overview of Drug Discovery and Role of basic Sciences New Approaches in Drug Discovery Pharmacological Screening Phases of Clinical TrialsIntroduction Phase I Phase II Studies Phase III Trials Phase IV Trials Phase 0 - Microdosing StudiesIntroduction Micro-dosing and Exploratory-IND StudiesCharacteristics of an Ideal Candidate Drug for Phase 0-Micro-dosing Studies Goals of Microdosing StudiesTechnical Advances Regulatory IssuesPatient’s PerspectiveInformed Consent Issues Single-dose Toxicity Study in Support of Micro-dosing StudiesAdvantages of Micro-dosingLimitations of Micro-dosing Conclusion Clinical Research PlanningIntroduction to Clinical Trials Types of Clinical TrialsThe Planning StepsClinical Research DesignIntroduction Elements of Trial DesignTypes of Clinical Trial DesignClinical Research ProtocolTitle Page Signature PageContents Page List of Abbreviations and Definitions Summary BackgroundTrial Objectives and Purpose Study DesignSubject Selection Subject Recruitment Trial Interventions Randomisations Blinding Data Statistical Considerations Compliance and Withdrawal Interim Analysis and Data MonitoringEthical Considerations Financing and Insurance Reporting and Publication Designing Case Report FormsIntroduction Uses of CRFWell-Designed CRF CRF Design Layout CRF Field Designs CRF Verification Before Use Elements of Trial Design Electronic Data Entry Forms Conclusion Points to Remember Process of Randomization in Clinical TrialsIntroduction Advantages of Randomization Types of Randomization Techniques of Randomisation Implementation of Randomization Procedure Investigational Medicinal ProductsDefinition Manufacturing, Packaging, Labeling, and Coding IMPsSupply and Handling IMPs Receipt of IMP, Inventory, Storage and Accountability Randomization Code Principles Applicable to Comparator Product Blinding Operations Recall, Return, Shipment and Destruction of IMP Multi-center Clinical TrialsIntroduction Advantages and DisadvantagesA Common Protocol A Coordinating Centre Comparability of Participating institutions Committees in a Multi-center Trial Statistical Issues Analysis of Results Multinational Clinical Trials Good Clinical Research PracticeIntroduction Definition of GCPOverview of the Clinical Research Process Principles of GCPRole and Responsibilities of SponsorIntroduction Contract Research Organization (CRO) The Sponsor and the investigational Products Sponsor and Record Access Safety Information Role and Responsibilities of Principal InvestigatorIntroduction Competencies and Responsibilities of the Principal Investigator Qualifications and Availability Adequate Resources Informed Consent Investigational Products Compliance with Protocol Monitoring and Auditing Source Data and Other Documentation Safety Issues and Reporting of Serious Adverse Events Premature Termination - Breaking the Treatment Code Progress Reports, Trial Outcome and Final Study Reports Ethical Consideration in Clinical Research – Special Reference to Developing CountriesIntroduction Individuals Involved With Ethical Issues Ethical Issues Related to Protocol Development and Study DesignIssues on Informed Consent Ethical Issues During Conduct of a Clinical Research Access to Post Trial Benefits Need for Developed Countries to Assist DevelopingCountries in Capacity Building Informed Consent in Clinical ResearchIntroduction Historical Background Elements of Informed Consent Language Used in Consent Forms Informed Consent Waiver Revising an Informed ConsentReconsenting Process Consent Obtained from Special Groups of Patients Monitoring in Clinical TrialsIntroduction Types of Monitoring in Clinical Trials Key Participant in Monitoring of Clinical Trial Quality Assurance in Clinical ResearchMonitoring-Details Presented in Chapter on Monitoring Audit Inspections Data Management Metrics Pharmacovigilance and Drug SafetyIntroduction Terms Commonly Used in Drug Safety The Specific Aims of Pharmacovigilance Definitions ADR Classification and Evolution Causality Assessment Scales Important of Post Marketing Surveillance and ADR Reporting Characteristics of a Good Adverse Drug Reaction Report Periodic Safety Update Report (PSUR) MedDRA or Medical Dictionary for Regulatory Activities Pharmacovigilance in India Data and Safety Monitoring Board and Monitoring PlanDefinition and Purpose Data Monitoring Committee Data Safety Monitoring Plan Standard Operating ProceduresIntroduction Standard Operating Procedures SOP Template Master Formulation Record Archiving Clinical Research DocumentsIntroduction Stake Holders What Documents Must Be Archived How long Should the Documents be Archived When to Archive Trail Master File (TMF) The Archive BuildingEvidence Based MedicineIntroduction and Overview History Types of EBM Categories of Evidence Categories of Recommendations Statistical Measures Quality of Clinical Trial Publications Limitations of Available Evidence Criticism of Evidence-Based Medicine Clinical Research Data ManagementIntroduction Protocol Randomisation Data Management Final Study Report Retension and Securing of Records Archiving by the Principle Investigator Archiving by the Sponsor Clinical Biostatistics(a) Biostatistics for Clinical Researcher26(a).1 Introduction26(a).2 Descriptive Statistics 26(a).3 Null Hypothesis and Alternative Hypothesis 26(a).4 Classifications of Data 26(a).5 Test of Hypothesis with the Correct Statistical Tests 26(a).6 Summary (b) Terminology Used in Biostatistics26(b).1 Introduction to Biostatistics 26(b).2 Terminology used in Biostatistics 26(b).3 Sampling Unit Glossary

Read more less

Book SynopsisAre herbal drugs totally devoid of adverse effects when used alone, as herbal formulations, or in concurrent use with modern medicines? Safety Concerns for Herbal Drugs examines that question and others like it to give you the information you need to judge for yourself the balance between the risks and benefits associated with the therapeutic use of medicinal plants. It stands out from other books by directing your attention to the aspects of safety and toxicity.The authors venture into the relatively unexplored (or deliberately hidden) side of the picture. They present a survey of approximately 1500 medicinal plants and herbal products, 59 global (from 27 countries) and 75 Indian examples of toxic and adverse effects and drug interactions. Additionally, they present the current status of regulatory laws and their enforcement in 73 countries to support their contention that such laws and enforcement are inadequate, and that herbal drugs are unscientifically beinTrade Review"Professors Divya Vohora and S.B. Vohora deserve our thanks for bringing out this very useful and informative book which will undoubtedly help in the rational use of herbal products."—Prof. Ranjit Roy Chaudhury, National Professor of Pharmacology; Advisor, Dept. of Health and Family Welfare, Govt. of National Capital Territory of Delhi, from the ForewordTable of ContentsIntroduction. Toxicity and Adverse Effects of Herbal Drugs. Global Picture. The Indian Scene. Regulatory Aspects. Critical Appraisal of the Available Data.

Read more less

Book SynopsisThis book traces the evolution of the pharmacist from compounder-dispenser to advisor counselor. It explores the impact on pharmacy of broad sociologic, demographic, and economic trends and examines controversial issues such as professional versus business objectives, managed cost care, coginitive services, pharmaceutical care, and the future roles

Read more less

Book SynopsisTopical and transdermal drug delivery systems (TDDs) have several advantages over traditional drug delivery methods, as they can be less invasive, more sanitary, more cost-effective, and may result in better patient compliance. TDDs play a significant role in therapeutics with a variety of preparations and approaches designed by expert formulation scientists. This volume integrates a wide variety of case studies, research, and theories to reveal their diversity and capture the novel approaches of transdermal and topical drug delivery employed by developers and content experts in the field. It provides an abundance of important information and state-of-the-art research on topical and transdermal drug delivery systems and addresses the basics of drug delivery systems, strategies to enhance permeation across membranes, and formulation and evaluation of diverse dosage forms.The volume presents an evaluation of the pros and cons of conventional drug delivery systems against TDDs and discusses the nuances of micro- and nano-systems in TDDs. The extraordinary packages of nano systems (vesicular systems, polymeric nanoparticles, nanoemulsion and dendrimers) are broadly discussed, and their applications are reviewed through a transdermal route.The book looks at TDDs and the main nanoparticles used in skin diseases and lesions of the aging, such as psoriasis, vitiligo, cancer, lesions of the aging and others. Chapters also discuss polymeric micelles in topical and transdermal delivery; microneedles; emulsion, nanoemulsion and microemulsion; TDDs in pulmonary drug delivery systems; nanoencapsulated nasal drug delivery systems; skin sensitivity and irritation testing for transposing transdermal drug delivery systems; and regulatory aspects of drug development for dermal products.Topical and Transdermal Drug Delivery Systems: Applications and Prospects will be a valuable resource for pharmaceutical scientists and researchers, industry professionals, and academicians and students of the pharmaceutical and biomedical sciences.Table of ContentsPART I: BASICS OF TRANSDERMAL DRUG DELIVERY SYSTEMS 1. Concepts and Applications in Topical and Transdermal Drug Delivery 2. Micro- and Nano-Systems in Transdermal Drug Delivery System 3. Advanced Topical and Transdermal Drug Delivery (TTDS) Used in Skin Diseases and Lesions of the Aging PART II: DIVERSE TRANSDERMAL DRUG DELIVERY SYSTEMS 4. Polymeric Micelles in Topical and Transdermal Delivery 5. Microneedles: An Innovative Strategy for Skin Drug Delivery, Diagnostic, and Cosmetologic Approaches 6. Emulsion, Nanoemulsion, and Microemulsion in Tdds 7. Pulmonary Drug Delivery Systems 8. Nanoencapsulated Nasal Drug Delivery System PART III: MISCELLANEOUS 9. Skin Sensitivity and Irritation Testing for Transposing Transdermal Drug Delivery System 10. Regulatory Aspects of Drug Development for Dermal Products

Read more less

Book SynopsisHigh throughput screening remains a key part of early stage drug and tool compound discovery, and methods and technologies have seen many fundamental improvements and innovations over the past 20 years. This comprehensive book provides a historical survey of the field up to the current state-of-the-art. In addition to the specific methods, this book also considers cultural and organizational questions that represent opportunities for future success. Following thought-provoking foreword and introduction from Professor Stuart Schreiber and the editors, chapters from leading experts across academia and industry cover initial considerations for screening, methods appropriate for different goals in small molecule discovery, newer technologies that provide alternative approaches to traditional miniaturization procedures, and practical aspects such as cost and resourcing. Within the context of their historical development, authors explain common pitfalls and their solutions. This book will serve as both a practical reference and a thoughtful guide to the philosophy underlying technological change in such a fast-moving area for postgraduates and researchers in academia and industry, particularly in the areas of chemical biology, pharmacology, structural biology and assay development.Table of ContentsPerspective/overview: State of the art in HTS at the academic-industry interface; Assay design and optimization; Assessment of available compound collections; Novel approaches to discovery and analysis of interesting compound combinations; Modern biophysical methods in target-based screening; Genetic perturbation methods; Understanding luminescence-based screens; Measuring interactions in live cells; Approaches to high-content imaging and multi-feature analysis; Profiling of genetically characterized cell systems; Multidimensional profile-based screening; Using biological systems that better recapitulate physiology; Phenotypic screens with model organisms; Encoded libraries; Modern virtual screening; Research data management; Small molecule bioactivity databases; Chemical biology in a pharma environment; Practical aspects of funding and executing high-throughput screens;

Read more less

Book SynopsisCompletely revised and updated, the 2nd edition of The Handbook of Medicinal Chemistry draws together contributions from authoritative practitioners to provide a comprehensive overview of the field as well as insight into the latest trends and research. An ideal companion for students in medicinal chemistry, drug discovery and drug development, while also communicating core principles, the book places the discipline within the context of the burgeoning platform of new modalities now available to drug discovery. The book also highlights the role chemistry has to play in wider target validation and translational technologies. This is a carefully curated compilation of writing from global experts using their broad experience of medicinal chemistry, project leadership and drug discovery and development from an industry, academic and charity perspective to provide unparalleled insight into the field.Table of ContentsPhysicochemical Properties; Synthesis in Medicinal Chemistry; Useful Computational Chemistry Tools for Medicinal Chemistry; Structure-based Design for Medicinal Chemists; Fragment-based Ligand Discovery; Machine Learning in Drug Design; Drug Metabolism; ADME Optimization in Drug Discovery; Molecular Biology for Medicinal Chemists; Assays; In Vitro Biology: Measuring Pharmacological Activity That Will Translate to Clinical Efficacy; Animal Models: Practical Use and Considerations; Bioinformatics for Medicinal Chemistry; Translational Science; Discovery Toxicology in Lead Optimization; Toxicology and Drug Development; Patents for Medicines; Target Validation for Medicinal Chemists; Lead Optimisation: What you should know!; Pharmaceutical Properties – The Importance of Solid Form Selection; The Medicinal Chemistry and Process Chemistry Interface; Clinical Drug Development; SMN2 Splicing Modification by Small Molecules – A Blueprint to Tackle the Underlying Genetic Cause of Many Underserved Diseases; The Discovery of Checkpoint Kinase 1 Inhibitors: From Fragments to Clinical Candidate; Medicinal Chemistry for Neglected Diseases – Malaria, Tuberculosis, Sleeping Sickness, Leishmaniasis and River Blindness; New Therapeutic Chemical Modalities: Compositions, Modes-of-action, and Drug Discovery

Read more less

Book SynopsisThe pharmaceutical industry is on the cusp of a new age, with the need for personalized therapy, more complex production processes, smaller batch sizes and rising manufacturing costs. It is necessary to continuously adapt to the rapidly changing environment using novel technology and improved operational efficiency and flexibility. To achieve this, intelligent manufacturing seems to be a definite answer. Pharma 4.0 is a framework for adapting digital strategies to the unique contexts of pharmaceutical manufacturing. This book provides a deep insight into key technologies that will modernize pharmaceutical manufacturing and facilitate digital transformation. Throughout the book we discuss technologies, application and challenges for applying digital technology in pharmaceutical industry, including: • Focus on an overview of Industry 4.0 and its application in the pharmaceutical field• Most recent advances in the pharmaceutical industry• Understanding the concepts of emerging technology trends for drug discovery.Table of Contents1. Digitalization in the Pharmaceutical Industry: Prioritization Throughout Digital Transformation 2. Applications of Industry 4.0 to the Pharmaceutical Sector 3. Blockchain in Pharmaceutical Industry: Opportunities and Challenges 4.Patient Monitoring using Blockchain 5. Potential of AI in Advancement of the Pharmaceutical Industry 6. Use of Artificial Intelligence and Robotics: Making the Drug Development Process Easier 7. Pharmaceutical Packaging: New Impulse Through Artificial Intelligence 8. Digital Assistant in Healthcare Systems: Application and Challenges 9. Deep Learning Techniques and Drug Release 10. Tissue Response Study Using Deep Learning Techniques 11. Issues and Challenges in Bioinformatics Tools for Clinical Trials 12. Advancement in Artificial Intelligence: Insights and Future Vision for Pharmacy Profession

Read more less

Book SynopsisA comprehensive look at existing technologies and processes for continuous manufacturing of pharmaceuticals As rising costs outpace new drug development, the pharmaceutical industry has come under intense pressure to improve the efficiency of its manufacturing processes. Continuous process manufacturing provides a proven solution.Table of ContentsAbout the Editors xvii List of Contributors xix Series Preface xxv Preface xxvii 1 Continuous Manufacturing: Definitions and Engineering Principles 1 Johannes Khinast and Massimo Bresciani 1.1 Introduction 1 1.1.1 Definition of Continuous Manufacturing 1 1.1.2 Continuous Manufacturing in the Pharmaceutical Industry 2 1.1.3 Our View of Continuous Manufacturing 3 1.1.4 Regulatory Environment 8 1.2 Advantages of Continuous Manufacturing 8 1.2.1 Flexibility 8 1.2.2 Effect on the Supply Chain 8 1.2.3 Agility and Reduced Scale-up Efforts 9 1.2.4 Real-Time Quality Assurance and Better Engineered Systems 9 1.2.5 Decentralized Manufacturing 10 1.2.6 Individualized Manufacturing 10 1.2.7 Reduced Floor Space and Investment Costs 10 1.2.8 More Efficient Chemistries 10 1.2.9 Societal Benefits 11 1.3 Engineering Principles of Continuous Manufacturing 11 1.3.1 Pharmaceutical Unit Operations 11 1.3.2 Fundamentals of Process Modeling 15 1.3.3 Balance Equations for Mass, Species, Energy and Momentum 16 1.3.4 Residence Time Distribution 20 1.3.5 Classical Reactor Types as a Basis for Process Understanding 21 1.3.6 Process Control, Modeling and PAT 24 1.3.7 Scale-Up 26 1.3.8 Dimensioning 27 1.4 Conclusion 28 References 30 2 Process Simulation and Control for Continuous Pharmaceutical Manufacturing of Solid Drug Products 33 Marianthi Ierapetritou, M. Sebastian Escotet-Espinoza and Ravendra Singh 2.1 Introduction 33 2.1.1 Scope and Motivation 33 2.1.2 Process Simulation 34 2.1.3 Process Control 36 2.2 Pharmaceutical Solid Dosage Manufacturing Processes 38 2.2.1 Overview 38 2.2.2 Continuous Manufacturing Processes 38 2.2.3 Continuous Process Equipment 39 2.3 Mathematical Modeling Approaches 44 2.3.1 First Principle “Mechanistic” Models 44 2.3.2 Multi-dimensional Population Balance Models 44 2.3.3 Engineering or Phenomenological Models 46 2.3.4 Empirical and Reduced Order Models 47 2.4 Unit Operations Models 48 2.4.1 Feeders 48 2.4.2 Blenders (Mixers) 56 2.4.3 Tablet Press 63 2.4.4 Roller Compactor 67 2.4.5 Wet Granulation 71 2.4.6 Drying 75 2.4.7 Milling/Co-milling 76 2.4.8 Flowsheet Modeling 77 2.5 Process Control of Continuous Solid-based Drug Manufacturing 81 2.5.1 Process Control Basics 83 2.5.2 Control Design of Continuous Pharmaceutical Manufacturing Process 84 2.6 Summary 93 Acknowledgments 94 References 94 3 Regulatory and Quality Considerations for Continuous Manufacturing 107 Gretchen Allison, Yanxi Tan Cain, Charles Cooney, Tom Garcia, Tara Gooen Bizjak, Oyvind Holte, Nirdosh Jagota, Bekki Komas, Evdokia Korakianiti, Dora Kourti, Rapti Madurawe, Elaine Morefield, Frank Montgomery, Moheb Nasr, William Randolph, Jean-Louis Robert, Dave Rudd and Diane Zezza 3.1 Introduction 108 3.2 Current Regulatory Environment 108 3.3 Existing Relevant Regulations, Guidelines, and Standards Supporting Continuous Manufacturing 108 3.3.1 ICH Guidelines 108 3.3.2 United States Food and Drug Administration Guidances 109 3.3.3 US FDA Guidance on Process Validation 109 3.3.4 American Society for Testing and Materials Standards 109 3.3.5 European Union Guidelines 110 3.4 Regulatory Considerations 110 3.4.1 Development Considerations for Continuous Manufacturing 111 3.4.2 Special Considerations for Control Strategy in Continuous Manufacturing 112 3.4.3 Stability Considerations for Continuous Manufacturing 114 3.5 Quality/GMP Considerations 115 3.5.1 Pharmaceutical Quality Systems 115 3.5.2 Batch Release 115 3.5.3 Startup and Shutdown Procedures 116 3.5.4 State of Control: Product Collection and In-process Sampling 117 3.5.5 Process Validation and CPV 117 3.5.6 Material Traceability in Continuous Manufacturing 119 3.5.7 Handling of Raw Material and In-process Material 119 3.5.8 Detection and Treatment for Non-conformity 119 3.5.9 Personnel Procedures and Training 120 3.5.10 Material Carry-over 120 3.5.11 Material Diversion 120 3.5.12 Production Floor Product Monitoring 121 3.5.13 Raw Material Variability 121 3.5.14 Cleaning Validation 121 3.5.15 Equipment Failure 122 3.6 Quality Considerations for Bridging Existing Batch Manufacturing to Continuous Manufacturing 122 3.6.1 Physicochemical Equivalence Considerations 123 3.6.2 Bioequivalence Considerations 123 3.7 Glossary and Definitions 123 3.7.1 Batch Definition 123 3.7.2 21cfr 210.3 124 3.7.3 Cfr 211 124 3.7.4 Ich Q 7 124 3.7.5 Ich Q 10 124 3.8 General Regulatory References 124 3.8.1 cGMP Guidance 125 4 Continuous Manufacturing of Active Pharmaceutical Ingredients via Flow Technology 127 Svetlana Borukhova and Volker Hessel 4.1 Introduction 127 4.2 Micro Flow Technology 128 4.2.1 Micromixing 129 4.2.2 Flow Reactors 130 4.2.3 Reaction Activation Tools 130 4.2.4 Downstream Processing 139 4.2.5 Process Analytical Technology and Automation 142 4.3 Multi-step Synthesis of Active Pharmaceutical Ingredients in Micro Flow 150 4.3.1 Aliskiren 151 4.3.2 Artemisinin 151 4.3.3 Ibuprofen 153 4.3.4 Gleevec 154 4.3.5 Nabumetone 155 4.3.6 Quinolone Derivative as a Potent 5HT 1B Antagonist 155 4.3.7 Rufinamide 155 4.3.8 Thioquinazolinone 156 4.4 Larger-scale Syntheses 156 4.4.1 Hydroxypyrrolotriazine (Bristol–Myers–Squibb) 156 4.4.2 2,2-Dimethylchromenes (Bristol–Myers–Squibb) 156 4.4.3 Fused-Bycyclic Isoxazolidines (Eli Lilly and Company) 158 4.4.4 7-Ethyltryptophol on the Way to Etodolac 158 4.4.5 6-Hydroxybuspirone (Bristol-Myers-Squibb) 159 4.5 Current Industrial Applications 160 4.6 Conclusion and Outlook 161 References 162 5 Continuous Crystallisation 169 Cameron Brown, Thomas McGlone and Alastair Florence 5.1 Introduction 169 5.2 Principles of Crystallisation 173 5.2.1 Supersaturation 173 5.2.2 Nucleation and Growth 176 5.2.3 Conservation Equations 180 5.3 Crystallisation Process Development 180 5.4 Continuous Crystallisers and Applications 185 5.4.1 Mixed Suspension Mixed Product Removal 186 5.4.2 MSMPR Cascade 193 5.4.3 Plug Flow Reactors 198 5.4.4 Impinging Jet 206 5.4.5 Microfluidics 207 5.5 Process Monitoring, Analysis and Control 207 5.5.1 Process Monitoring and Analysis 207 5.5.2 Crystallisation Control Strategies 211 5.6 Particle Characterisation 213 5.7 Concluding Remarks 215 References 217 6 Continuous Fermentation for Biopharmaceuticals? 227 L. Mears, H. Feldman, F.C. Falco, C. Bach, M. Wu, A. Nørregaard and K.V. Gernaey 6.1 Introduction 227 6.1.1 Definition of Fermentation 227 6.1.2 Production of Biopharmaceuticals 228 6.1.3 Structure of Chapter 228 6.2 Operation of Fermentation Systems 229 6.2.1 Comparison of Different Cultivation Systems 229 6.2.2 Monitoring of Continuous Fermentation Processes 232 6.2.3 Control of Continuous Fermentation Processes 234 6.3 Continuous Fermentation Examples 238 6.3.1 Continuous Ethanol Fermentation 238 6.3.2 Continuous Lactic Acid Fermentation 239 6.3.3 Single Cell Protein Production 240 6.4 Discussion 241 6.5 Conclusions 243 References 244 7 Integrated Continuous Manufacturing of Biopharmaceuticals 247 Alois Jungbauer and Nikolaus Hammerschmidt 7.1 Background 247 7.1.1 Current Status of Manufacturing of Biopharmaceuticals 247 7.1.2 Challenges to Developing Continuous Processes 249 7.1.3 Rationale for Continuous Biomanufacturing 250 7.2 Continuous Upstream Processing 251 7.2.1 Cell Lines and Cell Line Stability 251 7.2.2 Perfusion Reactor 252 7.2.3 Cell Retention Devices 252 7.2.4 Chemostat and Turbidostat 254 7.2.5 Overview of Products Produced by Continuous Upstream Processing 254 7.3 Continuous Downstream Processing 257 7.3.1 Overview of Unit Operations 257 7.3.2 Continuous Centrifuges 257 7.3.4 Continuous Chromatography 260 7.3.5 Continuous Precipitation 263 7.3.6 Continuous Formulation 266 7.4 Process Integration and Single Use Technology 266 7.4.1 Disposable Bioreactors 268 7.4.2 Disposable Unit Operations in Downstream Processing 268 7.4.3 Full Process Train 270 7.5 Process Monitoring and Control 270 7.6 Process Economics of Continuous Manufacturing 274 7.7 Conclusions 275 Acknowledgments 276 References 276 8 Twin-screw Granulation Process Development: Present Approaches, Understanding and Needs 283 A. Kumar, K.V. Gernaey, I. Nopens and T. De Beer 8.1 Introduction 283 8.2 Continuous Wet-granulation using a TSG 284 8.3 Components of High Shear Wet Granulation in a TSG 287 8.4 Material Transport and Mixing in a TSG 287 8.4.1 Granulation Time in a TSG 288 8.4.2 Mixing in a TSG 291 8.5 Granule Size Evolution During Twin-screw Granulation 294 8.5.1 Granule Size and Shape Dynamics in a TSG 295 8.5.2 Link Between RTD, Liquid Distribution and GSD in a TSG 295 8.6 Model-based Analysis of Twin-screw Granulation 298 8.6.1 Modelling RTD in a TSG 298 8.6.2 Tracking GSD in a TSG using PBM 300 8.7 Towards Generic Twin-screw Granulation Knowledge 302 8.7.1 Regime Map Approach 303 8.7.2 Particle-scale Simulation using DEM 305 8.8 Strengths and Limitations of the Current Approaches in TSG Studies 307 8.9 Glossary 308 References 309 9 Continuous Line Roller Compaction 313 Ossi Korhonen 9.1 Roller Compaction 313 9.2 Main Components of a Roller Compactor 313 9.3 Theory of Powder Densification in Roller Compaction 315 9.4 Johanson Model 317 9.5 Modified Johanson Model 319 9.6 Experimental Observations of Pressure Distribution from Instrumented Roller Compactors 322 9.7 Off-line Characterization of Ribbon Quality 324 9.8 In-line Monitoring of Roller Compaction Process 326 9.9 Formulative Aspects of Roller Compaction 328 9.10 Roller Compaction as a Unit Operation in Continuous Manufacturing 330 9.11 Process Control of Continuous Roller Compaction 332 9.12 Conclusions 333 References 334 10 Continuous Melt Extrusion and Direct Pelletization 337 Stephan Laske, Theresa Hörmann, Andreas Witschnigg, Gerold Koscher, Patrick Wahl, Wen Kai Hsiao and Johannes Khinast 10.1 Introduction 337 10.2 The Extruder 338 10.3 Feeding 341 10.3.1 Solid Feeding 341 10.3.2 LIW Screw Feeders 342 10.4 Twin-screw Extrusion 345 10.4.1 Counter-rotating Twin-screw Extruder 346 10.4.2 Co-rotating Twin-screw Extruder 347 10.5 Operation Point 347 10.6 Downstream Processing 349 10.6.1 Direct Shaping of Final Product 350 10.6.2 Intermediate Products 352 10.7 Continuous Manufacturing with HME 356 10.7.1 Process Understanding 356 10.7.2 Control Strategy 356 10.7.3 State of Control 357 10.7.4 Diversion of Material 357 10.8 PAT for HME 360 10.8.1 Near-infrared Spectroscopy 360 10.8.2 Raman Spectroscopy 360 10.8.3 Chemical Imaging 361 10.8.4 Particle Size Analysis 361 10.8.5 Optical Coherence Tomography 361 10.8.6 Data Processing 362 10.9 Process Integration into Computerized Systems 362 10.9.1 IT Structure of Supervisory Control Systems 364 10.9.2 Real-time Release Testing 365 10.10 Conclusion 365 References 366 11 Continuous Processing in the Pharmaceutical Industry: Status and Perspective 369 Richard Steiner and Maik Jornitz 11.1 Industry Drivers for Continuous Processing: Competitive Advantages 369 11.2 Continuous Manufacturing in Bioprocessing 371 11.2.1 Continuous Bioprocessing Enablers and Guidance 371 11.2.2 Process Technologies 372 11.2.3 Examples of Continuous Manufacturing 376 11.2.4 Economic and Design Implications 377 11.3 Continuous Manufacturing for Oral Solid Dosage Forms 381 11.3.1 Industry Approaches to the Implementation of cm 381 11.3.2 Typical Installation Layouts 383 11.3.3 Economic Justification and Business Excellence 387 11.4 The Pharmaceutical Supply Chain of the Future 395 11.4.1 Portable, Continuous, Miniature and Modular 395 11.4.2 The PCMM Concept 396 11.4.3 Discussion 399 11.5 Conclusion 400 Acknowledgments 401 References 401 12 Design of an Integrated Continuous Manufacturing System 405 Sarang S. Oka, M. Sebastian Escotet-Espinoza, Ravendra Singh, James V. Scicolone, Douglas B. Hausner, Marianthi Ierapetritou and Fernando J. Muzzio 12.1 Introduction 405 12.2 Step 1: Rough Conceptual Design 406 12.2.1 Type of Product 406 12.2.2 Type of Manufacturing Route – Direct Compaction, Wet Granulation or Dry Granulation 407 12.2.3 Flexible or Dedicated 408 12.2.4 Feeding Multiple Ingredients, Including Pre-blends 408 12.2.5 Strategy for Sensing and Control 409 12.2.6 Regulatory Strategy 409 12.3 Step 2: Material Property Screening 410 12.4 Step 3: Characterizing Unit Operation Using Actual Process Materials 412 12.4.1 Loss in Weight Feeders 412 12.4.2 Continuous Blenders 415 12.5 Step 4: Develop and Calibrate Unit Operation Models Including Process Materials 422 12.5.1 Application of the Model Development Algorithm in Pharmaceutical Problems 422 12.5.2 Recommendations for Developing a Unit Operation Model that Incorporates the Effects of Material Properties 423 12.6 Step 5: Develop an Integrated Model of an Open Loop System 424 12.6.1 Model Integration Basics 425 12.6.2 General Algorithm for Building an Integrated Model 425 12.7 Step 6: Examine Open Loop Performance of the Process 427 12.8 Step 7: Develop/Fine Tune PAT Methods for Appropriate Unit Operations 429 12.9 Step 8: Implement Open Loop Kit with PAT and IPCs Enabled 430 12.10 Step 9: Design of the Control Architecture 432 12.11 Step 10: Develop Integrated Model of Closed Loop System 436 12.12 Step 11: Implementation and Verification of the Control Framework 438 12.13 Step 12: Characterize and Verify Closed Performance 440 12.14 Conclusions 442 References 443 13 End to End Continuous Manufacturing: Integration of Unit Operations 447 R. Lakerveld, P. L. Heider, K. D. Jensen, R. D. Braatz, K. F. Jensen, A. S. Myerson, and B. L. Trout 13.1 Introduction 447 13.2 Process Description 448 13.2.1 Specific Benefits Obtained as a Result of cm 452 13.3 System Dynamics 452 13.3.1 Model-based Design and Control are the Governing Concepts in cm 452 13.3.2 The Absence of True Steady-state Operation and the Implications for Product Quality Control 453 13.3.3 Plant-wide Control for CM: Disentanglement of Times Scales and Control Objectives 455 13.3.4 Residence Time Distribution of a CM Process: Impact of Recycling 456 13.3.5 Disturbances, Nonlinearities, and Delays: Implications for Control 460 13.3.6 Startup and Shutdown Procedures 464 13.3.7 Buffering 465 13.4 Process Monitoring and Control 468 13.4.1 PAT Use in the Integrated Continuous Manufacturing Process 468 13.4.2 Soft Sensors and Prediction of Future Performance 469 13.5 Outlook: Opportunities for Novel Unit Operations and System Configurations 471 13.6 Summary and Closing Thoughts 477 References 480 14 Methodology for Economic and Technical Comparison of Continuous and Batch Processes to Enhance Early Stage Decision-making 485 Isabella Aigner, Wen-Kai Hsiao, Diana Dujmovic, Sven Stegemann and Johannes Khinast 14.1 Introduction 485 14.2 Technical–Economic Evaluation Methodology 486 14.2.1 Definition of the System Boundaries and Performance Targets 488 14.2.2 Modeling of the Process Chains 489 14.2.3 Performing Technical Feasibility and Risk Assessment 490 14.2.4 Evaluation of the Process Options 492 14.2.5 Calculation of Process Costs, Cost Comparison and Interpretation 498 14.2.6 Technology–Economic Profiling and Interpretation of Results 498 14.2.7 Performing Scenario, Sensitivity and Uncertainty Analysis 502 14.3 Conclusion 502 References 504 15 Drivers for a Change – Manufacturing of Future Medicines for Personalized Drug Therapies 507 Jukka Rantanen and Jörg Breitkreutz 15.1 Introduction 507 15.2 Personalized Medicine 508 15.2.1 Therapy Based on Individualized Needs for Different Patient Groups 508 15.2.2 Point of Care Diagnostics 509 15.3 Flexible Dosing with Innovative Products 510 15.4 Future Health Care Scenario 513 15.4.1 Enabling Manufacturing Technologies and Materials Science 513 15.4.2 The Regulatory Environment 518 15.4.3 Supply Chain 520 References 521 16 Perspectives of Printing Technologies in Continuous Drug Manufacturing 525 Niklas Sandler and Petri Ihalainen 16.1 Introduction 525 16.1.1 Printing Technologies – Enablers of Continuous Drug Manufacturing Approaches 525 16.2 Inkjet (Microdrop Generation Techniques) 527 16.2.1 Inkjet – Technical Description 527 16.2.2 Ink Development and Printability 531 16.2.3 Pharmaceutical Applications of Inkjet Printing 533 16.3 Flexographic Printing 535 16.3.1 Flexography – Technique Description 535 16.3.2 Pharmaceutical Applications of Flexographic Printing 537 16.4 Formulation Approaches for Inkjet and Flexography 538 16.5 Process Control and Process Analytical Technology for Continuous Printing Applications 539 16.6 From Laboratory-scale Printing Towards an Industrial Scale 540 16.7 Three-dimensional Printing/Additive Manufacturing 541 16.7.1 From Prototyping to Large-scale Manufacturing 542 16.7.2 Fused Deposition Modeling or Fused Filament Fabrication 543 16.7.3 Feedstock Material for FDM Printing 544 16.7.4 3D Printing Techniques used in the Biomedical and Pharmaceutical Area 545 References 546 17 Development of Liquid Dispensing Technology for the Manufacture of Low Dose Drug Products 551 Allan Clarke and Dave Doughty 17.1 Introduction 551 17.2 Background 552 17.3 Goals for the LDT Program 554 17.4 Overview of LDT 555 17.4.1 Formulation Overview 555 17.4.2 LDT Platforms 557 17.5 LDT Machine Design Details 559 17.5.1 Commercial Line Operation 559 17.5.2 Liquid Dispensing Cell 560 17.5.3 Solvent Evaporation 563 17.5.4 Inspection Systems on the Commercial Machine for Critical Quality Attributes 563 17.5.5 Pad Printing Cell 565 17.6 Scale-independence of the LDT Technology 566 17.7 Real-time Release Potential 567 17.8 Occupational Health, Environmental and Cleaning Considerations 570 17.8.1 Occupational Health 570 17.8.2 Environmental Controls/Cleaning 572 17.9 Conclusion 573 Acknowledgments 574 References 574 Index 577

Read more less

Book SynopsisPhysiologically Based Pharmacokinetic (PBPK) Modeling and Simulations The first book dedicated to the emerging field of physiologically based pharmacokinetic modeling (PBPK) Now in its second edition, Physiologically Based Pharmacokinetic (PBPK) Modelling and Simulations: Principles, Methods, and Applications in the Pharma Industry remains the premier reference book throughout the rapidly growing PBPK user community. Using clear and concise language, author Sheila Annie Peters connects theory with practice as she explores the vast potential of PBPK modeling for improving drug discovery and development. This fully updated new edition covers key developments in the field of PBPK modelling and simulations that have emerged in recent years. A brand-new section provides case studies in different application areas of PBPK modelling, including drug-drug interaction, genetic polymorphism, renal impairment, and pediatric extrapolation. Additional chapters address Table of ContentsPreface xix Acknowledgements xxi About the companion xxiii Section I. Principles, Methods, andBackground Information 1 1 A Review of Pharmacokinetic and Pharmacodynamic Principles 3 1.1 Introduction 4 1.2 Pharmacokinetic Principles 4 1.2.1 Routes of Drug Administration 4 1.2.2 Intravenous Bolus 4 1.2.3 Plasma Protein Binding and Blood–Plasma Ratio 9 1.2.4 Hepatic, Renal, and Biliary Clearances 12 1.2.5 Extravascular (Subcutaneous, Intramuscular, and Per Oral) Absorption 16 1.2.6 Absorption from Solid Dosage Forms 20 1.2.7 Role of Transporters in ADME 22 1.2.8 Linear and Non-Linear Pharmacokinetics 24 1.2.9 Intravenous Infusion, Repeated Dosing, Steady State Kinetics, and Accumulation 25 1.2.10 Active Metabolite and Prodrug Kinetics 28 1.3 Pharmacokinetic Variability 32 1.4 Pharmacokinetics Optimization in Drug Discovery 34 1.5 Pharmacodynamic Principles 34 1.5.1 Pharmacological Targets and Drug Action 35 1.5.2 Functional Adaptation Processes 39 1.5.3 Biomarkers, Surrogate Endpoints, and Clinical Endpoints 41 Keywords 47 References 48 2 A Review of Drug–Drug Interactions 51 2.1 Introduction 51 2.2 Drug Interactions Mediated by Enzymes and Transporters at Various Sites 54 2.3 Factors Affecting DDI 54 2.4 In Vitro Methods to Evaluate Drug–Drug Interactions 56 2.4.1 Candidate Drug as a Potential Perpetrator 57 2.4.2 Candidate Drug as a Potential Victim of Inhibition 58 2.5 Sources of Uncertainty 59 2.6 Therapeutic Protein–Drug Interaction 59 References 61 3 Modeling Pharmacokinetics, Pharmacodynamics, And Drug Interactions 65 3.1 Introduction 66 3.2 Modeling Pharmacokinetics 66 3.2.1 Compartmental Modeling of Linear and Nonlinear Pharmacokinetics (Enzyme and/or Transporter Capacity Limitation as Well as Target-Mediated Drug Disposition) 67 3.2.2 Population Pharmacokinetics 76 3.3 Pharmacokinetics/Pharmacodynamics and PK/Efficacy (Exposure/ Response) Modeling 80 3.3.1 PK/PD Models for Direct Effect: Sigmoid Emax Model 84 3.3.2 PK/PD Models for Direct Effect: Classical Receptor Theory 86 3.3.3 PK/PD Models Accommodating Delayed Pharmacological Response 89 3.3.4 PK/PD Models Accommodating Functional Adaptation Leading to Nonlinearity in Pharmacological Response with Respect to Time 96 3.3.5 PK/Efficacy Modeling 97 3.3.6 Translation of PK/PD and PK/Efficacy Modeling to Human 100 3.3.7 Average, Minimum, and Maximum Steady-State Concentrations 104 3.3.8 Estimation of Biologically Effective Dose in Human 107 3.3.9 Therapeutic Window 109 3.3.10 Static Models for Drug Interactions 109 3.4 Physiologically Based Pharmacokinetic (PBPK) Modeling and Its Integration with Pharmacodynamics and Efficacy Models 112 3.4.1 PK Modeling Compartmental vs PBPK 112 3.4.2 PK Variability: Population PK (popPK) Modeling vs PBPK 114 3.4.3 Integration of PBPK with PD, Quantitative Systems Pharmacology (QSP) Models or Quantitative Systems Toxicologyand Safety (QSTS) 114 3.4.4 PBPK Models to Evaluate Drug–Drug Interactions 115 3.4.5 DDI Risk Assessment with PBPK vs Static Models 118 Keywords 123 References 125 4 Physiological Model For Absorption 129 4.1 Introduction 130 4.2 Drug Absorption and Gut Bioavailability 130 4.2.1 Solubility and Dissolution Rate 130 4.2.2 Permeability: Transcellular, Paracellular, and Carrier-Mediated Pathways 136 4.2.3 Barriers to Membrane Transport – Luminal Degradation, Efflux, and Gut Metabolism 138 4.3 Factors Affecting Drug Absorption and Gut Bioavailability 140 4.3.1 Physiological Factors Affecting Oral Drug Absorption and Species Differences in Physiology 140 4.3.2 Compound-Dependent Factors 144 4.3.3 Formulation-Dependent Factors 144 4.4 In Silico Predictions of Passive Permeability and Solubility 147 4.4.1 In Silico Models for Permeability 147 4.4.2 In Silico Models for Solubility 147 4.5 Measurement of Permeability, Solubility, Luminal Stability, Efflux, Intestinal Metabolism 148 4.5.1 In Vitro, In Situ, and In Vivo Models for Effective Permeability 148 4.5.2 Measurement of Thermodynamic or Equilibrium Solubility 153 4.5.3 Luminal Stability 154 4.5.4 Efflux 154 4.5.5 In Vitro Models for Gut Metabolism and Estimation of Fraction Escaping Gut Metabolism 155 4.6 Absorption Modeling 156 Keywords 162 References 163 5 Physiological Model For Distribution 169 5.1 Introduction 170 5.2 Factors Affecting Tissue Distribution of Xenobiotics 170 5.2.1 Physiological Factors and Species Differences in Physiology 171 5.2.2 Compound-Dependent Factors 176 5.3 In Silico Models of Tissue Partition Coefficients 176 5.4 Measurement of Parameters Representing the Rate and Extent of Tissue Distribution 181 5.4.1 Assessment of Rate and Extent of Brain Penetration 181 5.5 Physiological Model for Drug Distribution 186 5.6 Drug Concentrations at the Site of Action 187 Keywords 189 References 189 6 Physiological Models For Drug Metabolism And Excretion 193 6.1 Introduction 193 6.2 Factors Affecting Drug Metabolism and Excretion of Xenobiotics 194 6.3 Models for Hepatobiliary and Renal Excretion 197 6.3.1 In Silico Models 197 6.3.2 In Vitro Models for Hepatic Metabolism 197 6.3.3 In Vitro Models for Transporters 200 6.4 Physiological Models 203 6.4.1 Hepato-Biliary Elimination of Parent Drug and Metabolites 205 6.4.2 Renal Excretion 208 References 211 7 Generic Whole-Body Physiologically Based Pharmacokinetic Modeling 217 7.1 Introduction 217 7.2 Structure of a Generic Physiologically-Based Pharmacokinetic (PBPK) Model 218 7.3 Somatic Compartments 220 7.3.1 Lungs (LU) 220 7.3.2 Arterial Blood (ART) 220 7.3.3 Venous Blood (VEN) 220 7.3.4 Stomach (ST) 220 7.3.5 Gut (GU) 220 7.4 Model Assumptions 221 7.5 PBPK Software 221 References 223 8 Pbpk Modeling Of Biotherapeutics 225 8.1 Introduction 226 8.2 Therapeutic Proteins 226 8.2.1 Peptides and Proteins 226 8.2.2 Antibodies and Antibody-Based Therapies 227 8.3 Pharmacokinetics of Therapeutic Proteins 234 8.3.1 Absorption 234 8.3.2 Renal Elimination 235 8.3.3 Immunogenicity 235 8.3.4 PEGylation 239 8.3.5 Transport by Convective and Transcytotic Extravasation 239 8.3.6 Catabolic Elimination (Proteolysis) 239 8.3.7 FcRn-Mediated Protection of IgGs Against Catabolism in FcRn-Rich Cells 241 8.3.8 Distribution and lymphatic elimination 242 8.3.9 Target-Mediated Drug Disposition and Receptor-Mediated Endocytosis 243 8.4 PBPK Modeling of Monoclonal Antibodies 244 8.4.1 Full PBPK Model for Monoclonal Antibodies 244 8.4.2 Minimal PBPK Model for Monoclonal Antibodies 253 8.5 Applications of PBPK Modeling of Monoclonal Antibodies 253 8.5.1 Pharmacokinetic Scaling 253 8.5.2 PBPK Integration with Pharmacodynamics of Monoclonal Antibodies 255 Keywords 156 References 258 9 Uncertainty And Population Variability 263 9.1 Introduction 264 9.2 Distinguishing Uncertainty and Variability 264 9.3 Sources of Uncertainty in Drug-related Parameters 264 9.4 Sources of Variability in System Parameters 266 9.5 Handling Population Variability 269 9.5.1 A POSTERIORI and A PRIORI Approaches to Handling Population Variability 269 9.5.2 Correlations Between Parameters 271 9.6 Uncertainty and Sensitivity Analysis 272 9.6.1 Local Sensitivity Analysis (One-at-a-time (OAT) and Derivative-based Methods) 272 9.6.2 Parameter Interactions and Global Sensitivity Analysis (GSA) 275 9.6.3 Global Sensitivity Analysis for Correlated Parameters (cGSA) 278 9.6.4 Applications of Sensitivity Analysis for PBPK Models 280 9.6.5 Limitations of Global Sensitivity Analysis 281 9.7 Uncertainty and Population Variability in Clinical Efficacy and Safety 282 Keywords 285 References 285 10 Nonclinical, Clinical, and Model-Informed Drug Development 293 10.1 Introduction: An Overview of Different Phases of Drug Development 294 10.2 Nonclinical Development 295 10.2.1 Preclinical Pharmacology, PK/PD Modeling, and Human Dose Prediction 297 10.2.2 Safety and Toxicology Studies 297 10.2.3 Studies with Radiolabeled Compound 298 10.3 Clinical Pharmacology Studies 302 10.3.1 First-in-Human, Single, and Multiple Ascending Dose Studies 302 10.3.2 Biopharmaceutics – Absolute Oral Bioavailability and Bioequivalence Study 304 10.3.3 Food Effect Study 304 10.3.4 Organ (Hepatic and Renal) Impairment Study 305 10.3.5 Pediatric Assessment 306 10.3.6 Mass Balance Study 307 10.3.7 Drug Interaction Study 307 10.3.8 Pharmacogenomics Study 308 10.3.9 Thorough QT (TQT) and Concentration QT (C-QT) Study 308 10.3.10 Immunogenicity Assays and Comparability Study for Biologics 309 10.3.11 Drug Labelling 309 10.4 Clinical Development in Oncology 310 10.5 Fast Track Routes to Address Unmet Medical Need in the Treatment of Serious Conditions 311 10.6 Model-Informed Drug Development 312 10.7 Physiologically Based Pharmacokinetic Models Complementing Clinical Pharmacology Studies 314 10.8 PBPK in Oncology 315 Regulatory Guidelines 316 References 319 Section II. Applications In The Pharmaceutical Industry 323 11 Overview Of Pbpk Applications 325 11.1 Introduction 325 11.2 PBPK Applications for Internal Decisions 326 11.3 PBPK Applications for Regulatory Filing 328 11.4 PBPK Modeling and Simulations Along the Value Chain 332 References 335 12 Applications Of Hypothesis Generation And Testing With Pbpk Models 337 12.1 Introduction 338 12.2 Hypothesis Generation and Testing with PBPK Models 338 12.2.1 Parameter Estimation from Intravenous Pharmacokinetic Profiles 338 12.2.2 Simulation of Oral PK Profile 341 12.2.3 Sensitivity Analysis 342 12.2.4 Verification of Hypotheses 346 12.2.5 Auto-inhibition of Drug-Metabolizing Enzymes, Uptake and Efflux Transporters 347 12.3 Hypothesis Generation and Testing Along the Value Chain 348 12.4 Conclusions 351 References 351 13 Applications of Physiologically Based Pharmacokinetic Models Integrated With Drug Effect Models (Pbpk/Pd) 353 13.1 Introduction: Integration of PBPK with Drug Effect Models 354 13.2 Dosing in Specific Populations 355 13.3 PBPK/PD for Bottom-Up Prediction of Inter-Patient Variability in Drug Response 357 13.4 PBPK/PD for Predicting the Inter-Patient Variability in Response to Prodrugs and Active Metabolites 358 13.5 PBPK/PD When Systemic Concentrations are not the Driver forDrug Response 359 13.5.1 Pre-Systemic Drug Target 359 13.5.2 Effect-Site Drug Concentration Different from Systemic Concentration 360 13.6 PBPK/PD for Monoclonal Antibodies 362 13.7 PBPK Models Linked to Quantitative Systems Pharmacology and Toxicology Models 363 13.7.1 PBPK–QST Models to Predict Drug-Induced Liver Injury 363 13.7.2 PBPK–QST Models to Predict Drug-Induced Cardiotoxicity 367 13.8 Conclusions 371 References 371 14 Pbpk Modeling and Simulations to Evaluate Clinical Drug-Drug Interactions 375 14.1 Introduction 376 14.2 Clinical DDI Studies and Modeling Approaches to Address Key Questions Related to Drug–Drug Interactions 376 14.2.1 Dedicated Clinical DDI Studies 378 14.2.2 Investigation of Phenotypic Effects for NMEs Predominantly Cleared by Polymorphic Enzyme or Transporter 379 14.2.3 Prospective Nested DDI Study 380 14.2.4 Cocktail DDI Study 381 14.2.5 PBPK Modeling and Simulations 381 14.2.6 Claims Relating to Results of DDI Studies 381 14.2.7 Impact on Label 382 14.3 PBPK Modeling of Different Types of Drug Interactions 382 14.3.1 PBPK Modeling Strategy: New Molecular Entity as Victim of CYP-Based Drug Interactions 382 14.3.2 PBPK Modeling Strategy: New Molecular Entity as Perpetrator of CYP-Based Drug Interactions 383 14.3.3 Non-CYP Based Drug Interactions 384 14.3.4 Transporter-Mediated Drug Interactions 385 14.4 DDI Predictions with PBPK Modeling and Simulations in Clinical Drug Development and Regulatory Submissions 387 14.4.1 DDI Predictions Along the Value Chain (Figure 14.5) 387 14.4.2 Possible Regulatory Outcomes, Based on the Predictions from a Verified and Validated PBPK Model 389 14.4.3 Regulatory Acceptance of PBPK Analyses Included in Regulatory Submissions 390 14.4.4 Predictive Performance of PBPK Models 391 14.5 Comparison of DDI Prediction Using Static and Dynamic Models 392 14.6 Conclusions 393 References 394 15 Dose Extrapolation Across Populations (Healthy Adult Caucasian To Pediatric, Pregnant Women, Different Ethnicities, Geriatric, Smokers And Obese Populations) 397 15.1 Introduction 398 15.2 PBPK Modeling Strategy for Dose Extrapolation to Specific Populations 398 15.3 Potential Benefits of PBPK Modeling for Dose Extrapolations to Specific Populations 399 15.4 Dose Extrapolations to Specific populations 404 15.4.1 Pediatric Starting Dose Selection 404 15.4.2 Pregnancy 406 15.4.3 Ethnicity – Japanese Population 407 15.4.4 Geriatric Population 408 15.4.5 Obese 409 15.4.6 Smokers 410 15.5 Conclusions 410 References 411 16 Dose Extrapolation Across Populations: Healthy Adult To Hepatic And Renal Impairment Populations 417 16.1 Introduction 418 16.2 Pathophysiological Changes in Organ Impairment 419 16.2.1 Hepatic Impairment 419 16.2.2 Renal Impairment 420 16.3 PBPK Modeling Strategy: Model Development, Verification, Validation, and Application 420 16.4 Benefits of Applying Validated PBPK Models to Organ-Impaired Populations 421 16.4.1 Enhancing Regulatory Confidence in the Application of PBPK Modeling for the Prediction of Exposure in the Organ-Impaired Population 421 16.4.2 Contribution of PBPK to the Totality of Evidence in Evaluating the Effect of Renal Impairment on Drug Exposure to Inform Labelling 424 16.5 Conclusions 425 References 426 17 Absorption-Related Applications Of Pbpk Modeling 429 17.1 Introduction 429 17.2 In Vitro – In Vivo Disconnect, Parameter Non-Identifiability and the Importance of Identifying Factors Limiting Absorption Through a Deconvolution of the Mechanisms Contributing to Gut Bioavailability 431 17.3 Non-Regulatory Internal Applications of PBPK Modeling and Simulations 433 17.3.1 Prediction of Fraction Absorbed 433 17.3.2 Oral Formulation Development 433 17.4 Regulatory Applications of PBPK Modeling and Simulations 438 17.4.1 Food–Drug Interactions 438 17.4.2 Interactions of a Poorly Soluble Weak Base with Acid Reducing Agents (ARAs) 444 17.4.3 In Vitro – In Vivo Correlations (IVIVCs) to Serve as Surrogate for Bioequivalence Testing (Case Study 12) 445 17.4.4 Biowaivers Based on Virtual Bioequivalence 449 17.4.5 Virtual Bioequivalence of Locally Acting Products (LAPs) 450 17.5 Conclusions 450 References 452 18 Regulatory Guidelines On The Reporting Of Physiologically Based Pharmacokinetic (Pbpk) Modeling Analysis 457 18.1 Introduction 457 18.2 Food and Drug Administration (FDA) Guidelines 458 18.3 European Medicines Agency (EMA) Guidelines 459 18.4 Comparison of FDA and EMA Guidelines 461 18.5 Risk-Informed Evidentiary Framework to Assess PBPK Model Credibility 463 18.6 Drug Model Verification of Locally Acting Products (LAPs) 464 References 466 19 Resolving The Challenges To Establishing Confidence In Pbpk Models 469 19.1 Introduction 470 19.2 Requirements for Developing Mechanistically Credible PBPK Models for the Three Broad Categories of Applications 470 19.3 Challenges to Developing Mechanistically Credible PBPK Models and Consequences 473 19.3.1 Model Building 473 19.3.2 Model Verification of Predicted Exposure and Validation of Predictive Performance 476 19.4 Resolving the Challenges to Developing Mechanistically Credible PBPK Models 476 19.5 Totality of Evidence 478 19.6 Conclusions 480 References 481 20 Epilogue 483 20.1 PBPK Modeling Successes 483 20.2 Challenges 484 20.2.1 Drug Model Parameterization 484 20.2.2 Knowledge Gaps in Physiological Parameters 485 20.2.3 Prospective Validation of Prediction Performance 485 20.3 Meeting the Challenges 485 20.4 Future Directions for PBPK Modeling 486 References 488 Section III. Case Studies Of Pbpk Applications In The Pharmaceutical Industry 491 Case Study 1 Hypothesis Testing (Solubility) 493 Case Study 2 Hypothesis Testing (Gastric Emptying) 499 Case Study 3 Hypothesis Testing (Intestinal Loss) 505 Case Study 4 Pbpk/Pd 509 Case Study 5 Drug–Drug Interaction (Inhibition) 515 Case Study 6 Drug–Drug Interaction (Induction) 521 Case Study 7 Genetic Polymorphism 527 Case Study 8 Pediatric Extrapolation 535 Case Study 9 Pregnancy 541 Case Study 10 Hepatic Impairment 547 Case Study 11 Renal Impairment 555 Case Study 12 Absorption – Ivivc 561 Appendices 567 Index 579

Read more less

Book SynopsisBioanalytical Aspects in Biological Therapeutics Deepen your understanding of how critical data are generated from bioanalysis In Bioanalytical Aspects in Biological Therapeutics, a team of renowned chemists, immunologists, and biologists delivers a timely and practical exploration of the diverse scientific and technical literature on the bioanalytical investigation of current biotherapeutics under development. The book discusses the challenges and considerations for bioanalytical support, covering a wide range of central topics in the field, including overview and basic immunology for testing of biological therapeutics, pharmacokinetic aspects, clinical immunogenicity prediction and testing, biomarker testing, biotransformation assessment for biologics, statistical aspects of bioanalytical testing, regulatory expectations, and more. Drug development and analysis professionals will learn how critical data are generated from bioanalysis and how proven tools and methods are applied to thTable of ContentsPreface viiXiaohui Xu and Weifeng Xu Foreword ixBinodh DeSilva Acknowledgments xiii About the Editors xv List of Contributors xvii 1 Overview of the Development of Biotherapeutics and the Role of Bioanalytical Sciences 1Robert Dodge 2 Basic Immunology for Bioanalytical Testing of Biotherapeutics 23Kang Chen and Weifeng Xu 3 Platform and Instrument Considerations in Bioanalytical Testing 51Dominic Warrino and Franklin Spriggs 4 Pharmacokinetic Assays 67Tong-Yuan Yang and Eric Wakshull 5 Recent Progress in Biomarker Bioanalysis and Target Engagement Assessment 87Yan G. Ni, Lindsay E. King and Carmen Fernández-Metzler 6 Immunogenicity Risk Assessment for Biotherapeutics 141Jochem Gokemeijer 7 Bioanalytical Strategy to Support Clinical Immunogenicity Assessment: Anti-drug Antibodies 159Ying Wang and Michael Luong 8 Bioanalytical Scheme for Antidrug Neutralizing Antibody Assays 185Weifeng Xu, Bonnie Wu and Jim McNally 9 Critical Reagents in Bioanalysis 209Yang Xu, Agostinho Gomes Rocha, Shannon Chilewski, Krisna C. Duong-Ly, Kun Yang and Jonathan Haulenbeek 10 Statistical Aspects of Bioanalytical Testing 239Arkady M. Gershteyn and Mark Ma 11 Bioanalytical Aspects in Biological Therapeutics: Biotransformation 277Wenying Jian, Cong Wei and Jinping Gan 12 New Modalities: Multidomain Therapeutics and Gene Therapy Programs 309Kelly Colletti and Mark Ma 13 Regulatory Aspects for Assay Development, Validation, and Sample Analysis 327Amy Lavelle and Megan Wiberg Index 355

Read more less

Book Synopsis

Read more less